https://trial.medpath.com/news/c243de644deb296d/astrazeneca-lse-azn-gains-fda-approval-for-fasenra-in-egpa-boosting-revenue 2024-09-20T10:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/9a841b2fbf6a4740/syncona-s-beacon-therapeutics-presents-trial-results-at-conference-morningstar 2024-09-20T10:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/d70d975ae733e53b/gprc5d-emerges-as-promising-target-in-multiple-myeloma-clinical-trials 2024-09-20T09:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/639abd8e0551648e/dad-s-epilepsy-med-use-won-t-harm-his-kids-study 2024-09-20T09:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/9f41420e52f9766f/novel-strategies-emerge-to-transform-cold-tumors-into-immunotherapy-responsive-hot-tumors 2024-09-20T09:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/ccdee821501a674e/cspc-pharmaceutical-s-new-hypertension-drug-trials-approved-tipranks-com 2024-09-20T09:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/1da0a28defa94016/yoga-other-exercise-can-curb-urinary-incontinence-in-women 2024-09-20T09:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/cb0cbcd494ce5639/are-antidepressants-being-overused-to-treat-seniors-pain 2024-09-20T09:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/5853ad4d5fd90a86/caring-for-horses-could-help-veterans-battling-ptsd 2024-09-20T09:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/3e8a36a42e7006ea/dad-s-epilepsy-med-valproate-use-won-t-harm-his-kids-study 2024-09-20T09:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/80e27b567d19f48f/european-ai-healthcare-startups-drive-medical-innovation-with-advanced-analytics-and-clinical-trial-solutions 2024-09-20T09:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/a1a99101b885e101/gc-therapeutics-raises-65m-to-accelerate-revolutionary-ipsc-cell-programming-platform 2024-09-20T08:42:38+00:00 weekly 0.7 https://trial.medpath.com/news/5e6f1cbdbe8bed51/astrazeneca-to-launch-palivizumab-synagis-in-india-express-pharma 2024-09-20T08:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/f639bf2b9574d22f/recent-breakthroughs-in-cancer-research-could-impact-these-key-companies 2024-09-20T07:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/1dba8f0d0ec02991/ai-language-model-achieves-87-accuracy-in-distinguishing-fibromyalgia-from-other-chronic-pain-conditions 2024-09-20T07:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/5d10dd420f207220/acelyrin-inc-announces-positive-results-from-global-phase-3-clinical-trial-of-izokibep 2024-09-20T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/d64d7552111f1371/new-treatment-strategies-emerge-for-managing-car-t-cell-therapy-side-effects 2024-09-20T05:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/80ba034844a33219/wockhardt-targets-global-launch-of-new-meningitis-drug-with-6-bn-market-potential-by-2026 2024-09-20T05:38:53+00:00 weekly 0.7 https://trial.medpath.com/news/a7df2706fcdd8cb3/dr-paulo-fontoura-md-phd-joins-stalicla-as-chief-scientific-and-clinical-development-advisor 2024-09-20T05:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/dce882ca664ee70b/hemophilia-b-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-20T04:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/c52b50edc69da77f/adrenoleukodystrophy-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-09-20T03:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/f823e012bc1bb175/hitting-psoriatic-arthritis-early-with-apremilast-helps-some-patients-trial-finds 2024-09-20T03:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/8635f813a272587e/mesoblast-meso-biotechnology-innovator-nearing-critical-milestones-for-life-changing-therapies 2024-09-20T03:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/d8135ffe8fdbcae1/pelareorep-plus-paclitaxel-extends-survival-in-hr-her2-breast-cancer 2024-09-20T02:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/5aed9c84c9d42152/study-reveals-biomarkers-that-predict-disability-worsening-in-multiple-sclerosis 2024-09-20T02:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/4ce4ab754eafbebb/euro-roundup-ema-finalizes-reflection-paper-on-establishing-efficacy-based-on-single-arm-trials 2024-09-20T01:44:59+00:00 weekly 0.7 https://trial.medpath.com/news/82a9e6365e211d04/roche-reports-positive-data-from-phase-iii-influenza-treatment-trial 2024-09-20T01:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/0f11e77bcce919c0/five-strategic-travel-solutions-to-boost-clinical-trial-diversity-and-patient-enrollment 2024-09-20T01:34:46+00:00 weekly 0.7 https://trial.medpath.com/news/c99cf2bb8ec6a269/rice-and-baylor-receive-2-8-million-to-suppress-inflammation-and-lung-damage 2024-09-20T00:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/796012786bd20190/checkmate-9er-post-hoc-analysis-seeks-to-identify-efficacy-biomarkers-for-nivolumab-onclive 2024-09-20T00:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/7443643bf850528a/immix-biopharma-stock-hits-52-week-low-at-1-74-amid-market-challenges-by-investing-com 2024-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c8a948277efb41f/kiromic-biopharma-activates-the-university-of-arizona-cancer-center-as-the-fifth-clinical 2024-09-19T23:27:34+00:00 weekly 0.7 https://trial.medpath.com/news/2f8644dfc232f7bb/beacon-therapeutics-presents-36-month-interim-results-from-phase-i-2-horizon-trial-biospace 2024-09-19T23:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/d7c6f0146f3af6f3/shaping-personalized-genetic-care-in-bc-ubc-faculty-of-medicine 2024-09-19T23:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/26d5f6668fde2536/fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer 2024-09-19T23:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/38ae5d1fb02ae19d/asu-biochemist-honored-for-lifetime-achievement-in-improving-human-health 2024-09-19T22:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/608fd9e2fe622bed/angiodynamics-initiates-recover-av-clinical-trial-assessing-alphavac-f1885-system-in 2024-09-19T22:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/30330faa178eb87b/mantle-cell-lymphoma-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-09-19T21:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/b476879577026afa/cybin-provides-corporate-update-on-upcoming-clinical-milestones-morningstar 2024-09-19T21:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/2786ebea25eade68/fda-clears-epitomee-an-ingestible-device-for-weight-management-neurology-advisor 2024-09-19T21:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/a8df5e2cc6f14820/genfit-reports-first-half-year-2024-financial-results-and-provides-corporate-update 2024-09-19T21:28:47+00:00 weekly 0.7 https://trial.medpath.com/news/ee03d3214ceb0dc2/esmo-2024-research-roundup-cancer-therapy-advisor 2024-09-19T21:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/8bdff387cb3b1471/earlier-info-on-financial-stress-obesity-and-second-cancers-carcinogenic-condoms 2024-09-19T21:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/5811fd9d37d4f85b/regulatory-actions-for-sept-19-2024-bioworld 2024-09-19T20:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/4ddb5bbdf1f3321d/rezolute-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-and-provides 2024-09-19T20:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/9f267fcf287bb541/rogaratinib-plus-atezolizumab-in-cisplatin-ineligible-patients-with-fgfr-rna-jama-network 2024-09-19T20:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/c46d396ff243fc5b/novo-nordisk-a-s-wegovy-r-recommended-by-the-european-regulatory-authorities-for-label 2024-09-19T19:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/ef4887ea64e9a20c/fda-approves-new-dosage-of-trastuzumab-biosimilar-for-her2-overexpressing-cancers 2024-09-19T19:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/8e0736953ed4ff7f/elanco-announces-fda-approval-and-launch-of-zenreliatm-ilunocitinib-tablets-offering-an 2024-09-19T19:21:32+00:00 weekly 0.7 https://trial.medpath.com/news/ff04f068c654027b/aplt-stock-soars-69-on-positive-update-on-galactosemia-drug-nda-yahoo-finance 2024-09-19T19:06:32+00:00 weekly 0.7 https://trial.medpath.com/news/3ca93d5052ccf14c/top-in-women-s-health-fda-warning-for-fezolinetant-trauma-may-be-toxic-for-brain-health 2024-09-19T18:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/c475dbd5b72766e5/bright-minds-biosciences-to-host-investor-analyst-kol-event-on-september-25th 2024-09-19T18:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/fb24d8744eeeff17/recon-fda-rejects-vanda-s-stomach-condition-drug-eu-authorizes-bavarian-mpox-vaccine 2024-09-19T18:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/f10372b16e8ef454/dr-srinivas-on-the-role-of-lutetium-lu-177-vipivotide-tetraxetan-in-mcrpc-onclive 2024-09-19T18:46:03+00:00 weekly 0.7 https://trial.medpath.com/news/5fe948e706a47988/imvanex-opinion-on-variation-to-marketing-authorisation-european-medicines-agency 2024-09-19T18:43:41+00:00 weekly 0.7 https://trial.medpath.com/news/65b29aea2e2c5925/summit-therapeutics-bests-merck-s-top-selling-drug-in-phase-iii-trial-seeking-alpha 2024-09-19T18:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/9865e1427852c18c/arterial-hypertension-clinical-trials-update-2024-nature 2024-09-19T18:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/fb76f022f1080720/clinical-trial-could-move-the-needle-in-traumatic-brain-injury-uc-san-francisco 2024-09-19T18:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/c5e613fdbc75c167/rintatolimod-plus-durvalumab-shows-early-disease-control-in-late-stage-pancreatic-cancer 2024-09-19T17:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/79c816fff5fb1f77/unlv-and-global-alzheimer-s-organization-collaborating-to-bring-next-gen-research-to-las-vegas 2024-09-19T16:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/958d10588d24387e/rapid-normalization-of-vitamin-d-deficiency-in-picu-vitdalize-kids-trials-journal 2024-09-19T15:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/bec8534ad33de4ca/phase-2-remark-trial-of-rvu120-doses-first-patient-with-lower-risk-mds 2024-09-19T15:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/be1b575b28c1113c/ema-recommends-extending-indication-of-mpox-vaccine-to-adolescents 2024-09-19T15:29:10+00:00 weekly 0.7 https://trial.medpath.com/news/6b61b3ff795cbdbf/certain-diabetes-drugs-may-lower-risk-of-dementia-and-parkinson-s-disease 2024-09-19T15:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/a04d9b5918a405c5/pharmacosmos-completes-strategic-acquisition-of-g1-therapeutics-in-multi-million-dollar-deal 2024-09-19T15:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/9268671205ff0b3c/fda-declines-to-approve-vanda-s-marketing-application-for-tradipitant-in-gastroparesis 2024-09-19T15:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/8b6be297543a2368/mpox-three-ongoing-vaccine-trials-to-watch-clinical-trials-arena 2024-09-19T15:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/ce6ab1803d8a86ee/trial-supports-uninterrupted-use-of-imatinib-for-gist-nci 2024-09-19T15:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/ce1bce7c69e03ccd/comparative-effects-of-drug-interventions-for-the-acute-management-of-migraine-episodes-in-adults 2024-09-19T15:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/dc782d458f004c25/overall-survival-with-cabozantinib-vs-sunitinib-in-advanced-papillary-renal-cell-carcinoma 2024-09-19T15:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/86b42c5f0effe4f0/chip-and-mcas-linked-to-risk-of-cancer-death-hematology-advisor 2024-09-19T15:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/ae7d88c6a870a93d/university-of-hong-kong-opens-first-clinical-trials-centre-with-private-hospital-cancer-a-focus 2024-09-19T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/2bd54bcd7f24de76/immunotherapy-clinical-trials-a-new-approach-to-treating-cancer-yahoo-finance 2024-09-19T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/89fa0c5616b0eca4/non-invasive-method-can-help-predict-survival-in-patients-with-liver-cancer-medical-xpress 2024-09-19T14:32:17+00:00 weekly 0.7 https://trial.medpath.com/news/f006ba9f6986043a/bavarian-nordic-gets-ema-approval-of-mpox-vaccine-for-adolescents-proinvestor 2024-09-19T14:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/c079b4a29bf05e94/22q11-2-deletion-syndrome-pipeline-market-research-report-2024-yahoo-finance 2024-09-19T14:19:51+00:00 weekly 0.7 https://trial.medpath.com/news/53116791fb4766dc/imac-holdings-inc-launches-subsidiary-ignite-proteomics-and-announces-groundbreaking 2024-09-19T14:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/a8aaebe554b28b7f/anticipated-cancer-antibody-drug-conjugates-fda-approval-by-2027-biospace 2024-09-19T13:52:43+00:00 weekly 0.7 https://trial.medpath.com/news/167ec59f5fbeed43/traveler-s-diarrhea-therapeutics-pipeline-market-report-2024-featuring-immuron 2024-09-19T13:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/ee9f7cab9ce25910/starton-successfully-delivers-cancer-drug-using-on-body-injector-clinical-trials-arena 2024-09-19T13:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/eb35f4fcbcb55cfc/newron-presents-h1-2024-results-and-provides-business-update-morningstar 2024-09-19T13:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/4e3cc552a61f6870/mda-awards-500000-grant-to-accelerate-als-research-globenewswire 2024-09-19T13:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/7c5da6bfcda47ab5/apnimed-announces-early-completion-of-enrollment-in-phase-3-synairgy-study-of-ad109 2024-09-19T13:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/02482d17a3b0be3a/covid-may-trigger-chronic-fatigue-syndrome-kaiser-permanente-division-of-research 2024-09-19T13:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/4f19d324796ebb7e/astrazeneca-announces-start-of-recruitment-in-two-new-phase-iii-trials-evaluating-saphnelo 2024-09-19T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/d12108c13d815df9/pharmacogenomics-pioneer-to-lead-first-multinational-study-university-world-news 2024-09-19T13:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/589a7884aab0f4a3/edgewise-therapeutics-announces-positive-top-line-data-from-phase-1-trial-in-healthy 2024-09-19T12:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/9dfddcd4c90ec52e/biosyngen-presents-pioneering-conditional-activation-armor-enhancement-super-t 2024-09-19T12:47:24+00:00 weekly 0.7 https://trial.medpath.com/news/c2045e361f76e79d/longboard-pharmaceuticals-receives-rare-pediatric-disease-designation-and-stock-titan 2024-09-19T12:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/1fb4d1b27c366727/oric-pharmaceuticals-maintains-buy-rating-amidst-competitive-landscape 2024-09-19T12:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/e11522fa0cfe284f/novel-ar-degraders-and-emerging-therapies-show-promise-in-advanced-prostate-cancer-treatment 2024-09-19T12:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/02c65b19e021bab5/gsk-builds-combo-case-for-rsv-shingles-shots-with-phase-iii-data-biospace 2024-09-19T12:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/cf046dfd2587a007/takeda-to-present-additional-clinical-trial-study-data-highlighting-the-impact-of-orexin 2024-09-19T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/9794a7ead603af13/kiromic-biopharma-advances-deltacel-01-into-expansion-phase-following-safety 2024-09-19T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/c286466952c7678f/quralis-announces-expansion-of-its-selective-kv7-2-7-3-ion-channel-opener-qrl-101-into-epilepsy 2024-09-19T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/3104f02cf0f6392a/skb264-innovative-cancer-antibody-drug-conjugate-clinical-trials-efficacy-insight 2024-09-19T11:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/549d1827c1c32a42/phase-3-study-shows-viability-of-177lu-psma-617-for-taxane-naive-metastatic-castration 2024-09-19T11:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/2eeee6485a1b6f73/xspray-pharma-announces-positive-fda-meeting-and-plans-for-dasynoc-nda-resubmission 2024-09-19T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/924a2d40d77a7f2f/irinotecan-hydrochloride-liposome-hr070803-in-combination-with-5-fluorouracil-and-nature 2024-09-19T11:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/9a670ac112ab0dcd/trastuzumab-biosimilar-and-pertuzumab-effective-safe-in-neoadjuvant-breast-cancer-therapy 2024-09-19T11:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/bf2193e2f4afb677/carematrix-launches-blinded-remote-monitoring-tech-for-clinical-trials 2024-09-19T10:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/516e258b4f205dfb/nurabio-closes-140m-fundraising-to-develop-neuroprotective-drugs 2024-09-19T10:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/2ecfca84178b6e0b/lecanemab-s-benefits-are-too-small-and-uncertain-the-bmj 2024-09-19T09:54:51+00:00 weekly 0.7 https://trial.medpath.com/news/3b27fe29d1a1b72e/bayer-s-nubeqa-breakthrough-in-prostate-cancer-with-46-risk-reduction-and-future 2024-09-19T09:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/71f579f57a6f620b/elacestrant-plus-abemaciclib-demonstrates-clinical-benefit-in-pretreated-er-her2-onclive 2024-09-19T09:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/c04f22b1045317ee/effectiveness-of-long-term-low-dose-aspirin-in-the-prevention-of-gastric-cancer-after 2024-09-19T09:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/532deb34155f365b/we-are-funding-hope-montreal-children-s-hospital-gets-a-boost-for-cancer-clinical-trials 2024-09-19T09:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/04c6b4ba6764d7a2/biopharma-services-announces-expansion-into-late-stage-patient-trials-and-integration 2024-09-19T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/49ad6a6bb3211db0/global-superbug-crisis-amr-deaths-projected-to-reach-39-million-by-2050-lancet-study-warns 2024-09-19T07:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/bf654f3d032fc63f/positive-pre-clinical-result-drive-to-human-trials-company-announcement-investegate 2024-09-19T06:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/ec5153d06e1a15a3/egetis-submits-a-patent-application-to-the-united-states-patent-and-trademark-office-for 2024-09-19T05:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/e2a111636de9f6df/flatiron-health-expands-its-mission-to-make-trials-more-pragmatic 2024-09-19T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/c414ed00ee2232c9/lupin-partners-with-takeda-to-launch-novel-acid-blocker-vonoprazan-in-india 2024-09-19T02:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/c0f43c8be7714888/three-major-trends-reshaping-precision-medicine-ai-crispr-and-mrna-technologies-lead-innovation 2024-09-19T00:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/da687612483a87bc/transcenta-updates-encouraging-efficacy-data-from-first-line-triple-combo-trial-of-pr-newswire 2024-09-19T00:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/498702c9c068d2d0/clinical-trials-at-sidra-medicine-offers-hope-to-children-with-rare-diseases 2024-09-19T00:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/ccfe94a6a5fa1484/study-finds-no-short-term-benefit-of-adding-revascularization-to-medical-therapy-for-carotid-stenosis 2024-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee85f75382378434/sprc-scisparc-ltd-ordinary-shares-latest-stock-news-market-updates 2024-09-18T23:54:58+00:00 weekly 0.7 https://trial.medpath.com/news/4fe081201ca90a4d/organon-gets-more-skin-in-the-game-by-acquiring-roivant-s-dermatology-subsidiary 2024-09-18T23:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/0b7463dc1014e3d8/reactivating-interest-in-hsv-shedding-after-solid-organ-transplant-fred-hutchinson-cancer-center 2024-09-18T22:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/3eae75a5369ee152/improving-car-t-cell-efficacy-via-new-manufacturing-process 2024-09-18T22:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/40de547246bcb3d2/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-classic-galactosemia 2024-09-18T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/1267f5226ceceb5a/new-briumvi-r-ublituximab-xiiy-data-from-the-enhance-phase-3b-study-show-rapid-30 2024-09-18T21:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/3d7832064f225d3b/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-biospace 2024-09-18T21:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/237680b989c9c5da/bone-marrow-cancer-drug-shows-success-in-treatment-of-rare-blood-disorder 2024-09-18T21:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/8ff9714f34130575/lenvatinib-combo-yields-substantial-antitumor-activity-in-endometrial-cancer 2024-09-18T21:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/557c737ef20451c9/4dmt-shares-data-from-phase-1-2-prism-clinical-trial-4front-phase-3-study-design 2024-09-18T21:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/aab0f5dc64153e89/addition-of-palliative-radiotherapy-to-best-supportive-care-in-painful-hepatic-cancer 2024-09-18T20:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/4ec453b1d19119e4/new-study-challenges-amyloid-beta-theory-on-cause-for-alzheimer-s-disease 2024-09-18T20:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/5ba547efd18e6910/park-and-patel-explore-advances-in-egfr-nsclc-from-asco-2024-onclive 2024-09-18T20:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/93d959df33665d39/phelps-health-offers-inspire-therapy-for-obstructive-sleep-apnea-news-phelpscountyfocus-com 2024-09-18T20:26:13+00:00 weekly 0.7 https://trial.medpath.com/news/91ecbfe6e078a460/ossium-treats-first-leukaemia-patient-in-cryopreserved-bone-marrow-trial 2024-09-18T20:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/47e13158026b1d5d/vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda 2024-09-18T20:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/4552c044fee97e72/medicaid-might-help-increase-clinical-trial-diversity-penn-ldi 2024-09-18T20:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/40c5f5631c2a4c53/scisparc-takes-major-step-forward-with-ind-application-submitted-to-the-fda-for-phase-iib 2024-09-18T20:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/ad69d4f3f25a569d/fewer-cancer-drugs-exempt-from-pediatric-testing-after-race-act-healio 2024-09-18T20:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/535739c00eaf7915/exploring-advancements-in-higher-risk-mds-targeted-oncology 2024-09-18T20:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/293d1e4f35fb507f/new-trial-to-test-potential-treatment-for-chronic-kidney-disease-university-of-oxford 2024-09-18T19:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/651c1abc0661fa9e/personalized-treatment-could-be-key-to-tackling-uncontrolled-high-blood-pressure 2024-09-18T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/a516ffa237970f1c/implantica-s-anti-reflux-device-shows-positive-two-year-results-clinical-trials-arena 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/news/6e342798cade6337/aclaris-doses-first-subject-in-phase-iia-atopic-dermatitis-treatment-trial 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/news/3b4ab90e295b3f08/medical-breakthrough-new-drug-being-tested-to-help-treat-strokes-krgv 2024-09-18T19:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/3e1008e463e4225d/alteogen-seeks-approval-for-aflibercept-biosimilar-in-korea-goodwin-jdsupra 2024-09-18T18:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/e00a4d83013d97a8/sunrise-4-neoadjuvant-tar-200-cetrelimab-is-linked-with-strong-pcr-por-in-mibc 2024-09-18T18:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/42e5560fd79bfb2c/oral-geographic-atrophy-treatment-misses-primary-endpoint-in-phase-3-study-healio 2024-09-18T17:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/ca5e855dd3976d54/plaquetec-and-rxcelerate-collaborate-on-early-phase-drug-discovery-for-coronary-artery-disease 2024-09-18T17:18:01+00:00 weekly 0.7 https://trial.medpath.com/news/39450d7611c982df/dr-toni-choueiri-on-key-takeaways-from-tinivo-2-trial-urology-times 2024-09-18T17:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/7e7cb309fc0e3dc7/kesimpta-shows-promise-in-reducing-relapsing-multiple-sclerosis-disability-progression 2024-09-18T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/428c3968a91349b7/fda-grants-orphan-drug-designation-to-cf33-hnis-for-cholangiocarcinoma-onclive 2024-09-18T16:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/04bc9ba7c100659b/usc-launches-study-on-how-type-1-diabetes-affects-childhood-brain-development 2024-09-18T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/011ba3b85fd74072/nih-led-studies-point-to-potential-development-of-a-cataract-drug 2024-09-18T15:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/bd0088deca9edfd8/io-therapeutics-inc-presented-data-from-studies-of-irx4204-the-company-s-phase-ii-morningstar 2024-09-18T15:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/f42e93bf7df6252e/esmo-data-show-durvalumab-improves-overall-survival-event-free-survival-pharmacy-times 2024-09-18T15:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/e107640fb8716471/dato-dxd-demonstrates-efficacy-safety-in-platinum-resistant-ovarian-and-endometrial-cancers 2024-09-18T14:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/07c5e98e447e2903/it-s-past-time-to-end-hiv-wonder-drug-experimentation-in-africa-stat-news 2024-09-18T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/8c78a49e2e18a972/kaida-biopharma-launches-social-media-channels-morningstar 2024-09-18T14:18:29+00:00 weekly 0.7 https://trial.medpath.com/news/29c2333cfc2cbc3b/research-study-participants-are-more-engaged-when-they-see-their-test-results-uic-today 2024-09-18T14:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/cc3db15fc04610e3/glycomine-receives-fda-fast-track-designation-for-glm101-for-the-treatment-of-pmm2-cdg 2024-09-18T13:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/482797060df08405/azitra-receives-fast-track-designation-for-atr-04-for-skin-rash-from-egfr-inhibitors 2024-09-18T13:37:05+00:00 weekly 0.7 https://trial.medpath.com/news/acf80cc26cb6aa6b/medtronic-teases-positive-data-adaptive-deep-brain-stimulation-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/news/df41a5d03e9b6cc4/fda-lifts-partial-clinical-hold-on-vigil-neuroscience-s-phase-i-vg-3927-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/news/42ef5bf20a9e01ab/insilico-medicine-reports-positive-phase-iia-results-for-ism001-055-a-novel-first-in-class 2024-09-18T13:30:27+00:00 weekly 0.7 https://trial.medpath.com/news/e739e339509f4ced/tap-into-the-a4-study-for-unprecedented-alzheimer-s-clinical-trial-data 2024-09-18T13:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/3041ac8dbcd5fec7/praxis-precision-s-relutrigine-reduces-seizures-in-rare-epileptic-disorders-in-phase-2-clinical-trials 2024-09-18T12:59:14+00:00 weekly 0.7 https://trial.medpath.com/news/5ba7a0b4e08914c3/novo-nordisk-starts-new-phase-iii-study-with-wegovy-successor-medwatch 2024-09-18T12:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/371a253485544091/plus-therapeutics-showcases-new-interim-respect-gbm-phase-2-trial-data-at-the-2024 2024-09-18T12:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/c98c209dbb211687/briacell-announces-fda-authorized-expanded-access-policy-for-metastatic-breast-cancer-patients 2024-09-18T12:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/394ca99eab420c77/new-data-to-be-presented-from-eftisarc-neo-phase-ii-globenewswire 2024-09-18T12:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/ee75601d7898e464/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-420mg 2024-09-18T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/6fa59b76e82ca59c/biosyngen-s-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii 2024-09-18T11:31:06+00:00 weekly 0.7 https://trial.medpath.com/news/c53d85c58f183be6/mira-pharmaceuticals-advances-ketamir-2-development-following-phase-1-design 2024-09-18T11:25:29+00:00 weekly 0.7 https://trial.medpath.com/news/ee27644a28fd618a/satellos-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-sat-3247 2024-09-18T11:22:22+00:00 weekly 0.7 https://trial.medpath.com/news/cf0d8d6223d17d31/planned-for-a-marathon-but-it-turned-into-a-sprint-a-blog-by-tunde-oremule-ent-registrar 2024-09-18T11:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/1c9169756ca51549/alk-renal-cell-carcinoma-case-study-demonstrates-success-of-precision-medicine-approach 2024-09-18T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2c2d1e90c5e8d3ad/mannkind-announces-clearance-from-pmda-to-initiate-phase-3-clinical-trial-icon-1-biospace 2024-09-18T10:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/751b4ca1422fb6fb/invion-s-inv043-candidate-demonstrates-positive-results-in-phase-ii-prostate-cancer-trial 2024-09-18T09:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/811f385fcaa995a3/most-promising-new-drugs-for-hidradenitis-suppurativa-with-raj-chovatiya-md-phd 2024-09-18T09:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/7b186e601025097b/post-op-keytruda-boosts-bladder-cancer-outcomes 2024-09-18T09:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/76ddc4fd2b49779b/imcheck-receives-fda-fast-track-designation-for-ict01-in-globenewswire 2024-09-18T09:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/93b1bd7cd555233f/neoadjuvant-therapy-could-improve-outcomes-for-nasal-and-paranasal-sinus-cancer 2024-09-18T09:02:20+00:00 weekly 0.7 https://trial.medpath.com/news/d60d43e112485b13/merit-medical-touts-positive-six-month-data-from-wave-trial 2024-09-18T08:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/28564e4bd4137e72/nicox-announces-approval-of-zerviate-in-china-biospace 2024-09-18T08:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/705041783d0b5f6e/fasenra-egpa-us-fda-approval-astrazeneca-cision-news 2024-09-18T08:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/5cb523fa6126234c/sensorion-reports-2024-first-half-results-and-highlights-recent-updates-yahoo-finance 2024-09-18T06:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/fcad2bdc840ebb8b/wclc-2024-study-reveals-multiple-hidden-burdens-of-lung-cancer-treatment-financial-time-and-sexual-health-impacts 2024-09-18T06:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/4279ad4416c9c3aa/poolbeg-pharma-patent-portfolio-significantly-strengthened-expanded 2024-09-18T06:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/1b84559171d065e2/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims 2024-09-18T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/666bda45894fd327/brenus-pharma-raises-25-million-to-accelerate-clinical-trials-of-its-precision-cancer-vaccines 2024-09-18T06:29:04+00:00 weekly 0.7 https://trial.medpath.com/news/8dcf64beb8fc24ba/fda-formalizes-protocol-for-international-cancer-trials-stat-news 2024-09-18T06:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/bb0bd23d339c241a/valneva-seeks-approval-to-expand-ixchiq-chikungunya-vaccine-use-to-adolescents-in 2024-09-18T05:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/c6e17ae92d78a254/baptist-health-achieves-52-reduction-in-high-risk-infusion-errors-through-system-wide-pump-standardization 2024-09-18T05:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/0dfad1d21fcba95c/lymphedema-risk-no-higher-with-3-week-rt-regimen-in-early-breast-cancer 2024-09-18T04:03:40+00:00 weekly 0.7 https://trial.medpath.com/news/c4beba5245b24e47/autobahn-therapeutics-starts-trial-of-abx-002-for-major-depressive-disorder-in-adults 2024-09-18T03:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/bc244dfa7282a119/eli-lilly-nyse-lly-gains-fda-approval-for-ebglyss-expands-strategic-alliances-for 2024-09-18T02:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/ebecef1b3de4bb8f/perioperative-durvalumab-reduced-risk-of-recurrence-or-death-vs-neoadjuvant-the-asco-post 2024-09-18T01:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/548812098abee9b8/breakthrough-in-long-covid-an-investigator-initiated-trial-iit-with-hyundai-bioscience-s 2024-09-18T01:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/1ddce7031e053652/novel-triplet-regimen-yields-promising-response-in-advanced-phase-chronic-myeloid-leukemia 2024-09-18T00:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/72b4e47754dfc57a/bristol-myers-squibb-initiates-two-phase-i-trials-testing-novel-therapies-for-advanced-solid-tumors-and-relapsed-refractory-lymphomas 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b694a6ade6107c58/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-healthy-children-under-5 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bacd8c36adeb528d/upfrontpsma-177lu-psma-617-shows-potential-in-mhspc-urology-times 2024-09-17T23:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/3e8fb932c8ef315d/ai-driven-saliva-test-revolutionizes-epilepsy-home-care-mirage-news 2024-09-17T23:24:43+00:00 weekly 0.7 https://trial.medpath.com/news/38c75f03455693c8/fda-approves-pembrolizumab-chemo-in-unresectable-pleural-mesothelioma 2024-09-17T23:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/0847544b1e08c8f9/cdmo-kincell-secures-partnership-to-manufacture-cell-therapy-for-clinical-trials 2024-09-17T23:22:16+00:00 weekly 0.7 https://trial.medpath.com/news/08ba6a2151e21de9/trishula-therapeutics-reports-results-from-phase-i-trial-of-pancreatic-cancer-drug 2024-09-17T22:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/c8d9d6c1793ee14c/microbot-medical-announces-the-successful-enrollment-of-50-of-the-patients-in-its-pivotal 2024-09-17T22:36:55+00:00 weekly 0.7 https://trial.medpath.com/news/0213c8394fecfc44/biogen-s-new-drug-submission-for-omaveloxolone-accepted-for-priority-review-by-health 2024-09-17T22:36:54+00:00 weekly 0.7 https://trial.medpath.com/news/06189a4f180aa5a5/sysmex-inostics-ras-raf-seq-assay-receives-new-york-state-department-of-health 2024-09-17T22:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/d7e354a020264053/lisata-therapeutics-announces-first-patient-treated-in-the-second-line-biospace 2024-09-17T22:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/e81f705dcb5f3366/q-a-ethical-decision-making-around-neurotechnology-treatments-penn-state-university 2024-09-17T22:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/43d929e4dbfdb9f2/cms-new-breakthrough-device-policy-shows-little-promise-law360 2024-09-17T21:23:35+00:00 weekly 0.7 https://trial.medpath.com/news/b892ace819f0a1c9/dr-mehta-on-fda-approved-treatment-options-in-later-line-hematologic-malignancies 2024-09-17T21:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/32129a91738cdd38/patients-at-last-begin-receiving-vertex-crispr-and-bluebird-sickle-cell-gene-therapies 2024-09-17T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/07edb96341689ac6/fda-s-final-guidance-on-dcts-adds-clarity-on-hcp-task-log-inspection-requirements-data-variability 2024-09-17T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/0f853c2fff498523/should-young-kids-take-the-new-anti-obesity-drugs-what-the-research-says-nature 2024-09-17T21:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/53ca8409b5731f8e/keytruda-keys-in-on-survival-promising-results-in-high-risk-early-stage-tnbc-from-keynote-522 2024-09-17T20:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/f202fd031010e1ca/an-oral-benzothiophene-bdk-inhibitor-disclosed-by-pfizer 2024-09-17T20:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/685ba7a5c6a7a812/study-oncology-accelerated-approvals-are-often-based-on-non-comparative-trials-raps 2024-09-17T20:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/e7cbfdc0eb4acc20/elon-musk-s-neuralink-secures-fda-breakthrough-status-for-vision-implant 2024-09-17T20:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/2a672482f4e5cd5d/bubs-australia-asx-bub-one-of-the-few-infant-formula-stocks-building-a-post-china-future 2024-09-17T20:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/f397add8bacbcc1e/senseonics-receives-fda-clearance-for-one-year-cgm-medtech-dive 2024-09-17T19:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/22e2ed9418711b07/metabolic-dysfunction-associated-steatohepatitis-mash-clinical-program-design 2024-09-17T19:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/aa0ad34ff59cb747/asv-is-not-a-generic-device-sleep-review 2024-09-17T19:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/3100c8442b3607ec/musk-s-neuralink-gets-fda-s-breakthrough-device-tag-for-blindsight-implant-cna 2024-09-17T19:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/f7a8f77186e4cf24/i-choose-to-climb-instead-of-fall-nih-medlineplus-magazine 2024-09-17T19:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/ca56e494e4c2ec1a/quidelortho-receives-fda-approval-for-std-assay-san-diego-business-journal 2024-09-17T19:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/1e4d58b2f3753cd3/enhanced-cytosine-base-editing-for-duchenne-muscular-dystrophy-crispr-medicine 2024-09-17T18:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/ba7a145c12b821c3/sparta-biomedical-reports-treatment-of-first-patients-with-breakthrough-device-ormi 2024-09-17T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/004d5ad34ce34a67/allclinicaltrials-com-empowering-patients-with-easy-access-to-clinical-trials-the-globe-and-mail 2024-09-17T18:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/f717840436864e6b/data-roundup-august-2024-features-updates-in-car-t-mrna-therapy-and-gamma 2024-09-17T18:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/df80403f0ae447c2/fred-saad-md-on-implications-of-phase-3-aranote-data-in-mhspc-urology-times 2024-09-17T18:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/f1a2916e64c14cb0/cms-finalizes-new-transitional-coverage-for-emerging-technologies-tcet-pathway-to 2024-09-17T18:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/c45a58a946340c54/benmelstobart-plus-anlotinib-demonstrates-efficacy-in-frontline-advanced-rcc-onclive 2024-09-17T18:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/6daec83077789a07/iview-therapeutics-inc-completes-patient-recruitment-for-phase-1-2-trial-of-ivw-1001 2024-09-17T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/ea23bdffb42190f1/damaged-small-intestine-repaired-with-hpsc-derived-organoids-drug-target-review 2024-09-17T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/4d8dcd60405bd7eb/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression 2024-09-17T16:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/a1ffd440207cd7af/leigh-s-lost-and-found-digital-extra-area-dogs-participate-in-study-to-extend-lives-ky3 2024-09-17T16:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/a43166975e75aa8e/canaccord-highlights-arcturus-stock-potential-amid-regulatory-wins-investing-com 2024-09-17T16:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/ef48cae31d93d55e/medical-marijuana-users-see-short-term-gains-in-health-related-quality-of-life-study-finds 2024-09-17T16:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/5b0f0977a9ed38ab/desai-sethi-research-team-identifies-how-to-reverse-the-genetics-of-poor-prostate-cancer 2024-09-17T16:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/9cb47c97832b0f09/use-of-metformin-in-adults-with-diabetes-linked-to-lower-risk-of-long-covid 2024-09-17T16:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/314ba837b154cfa6/ev-pembrolizumab-yields-pfs-os-orr-benefits-regardless-of-nectin-4-level 2024-09-17T16:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/255d03f19ed033a2/new-drug-target-discovered-for-aggressive-prostate-cancer 2024-09-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/08eb3f63347a6d00/esmo-2024-eli-lilly-brings-the-competition-to-novartis-with-new-results-in-mcrpc 2024-09-17T15:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/a1e9e9fafe5b04d8/tislelizumab-receives-israeli-approval-in-unresectable-or-metastatic-escc-onclive 2024-09-17T15:43:37+00:00 weekly 0.7 https://trial.medpath.com/news/b65e2bdef35ca2ae/boehringer-gets-the-first-phase-iii-hit-in-ipf-for-a-decade-scrip-citeline 2024-09-17T15:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/9cde540a820946a4/obesity-pill-races-heats-up-as-novo-roche-and-terns-share-data-biospace 2024-09-17T15:23:11+00:00 weekly 0.7 https://trial.medpath.com/news/4b465be419b1bae3/tomosynthesis-more-effective-than-mammography-for-breast-cancer-screening 2024-09-17T14:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/f55e102e6811ddc8/survival-improves-with-atezolizumab-switch-therapy-in-braf-melanoma 2024-09-17T14:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/2d7c4e219b6c94db/esmo-24-pfizer-to-take-cancer-weight-gain-drug-into-phase-iii-scrip-citeline 2024-09-17T14:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/12223634f89b67a9/cps-technologies-corporation-announces-phase-ii-award-from-the-department-of-energy 2024-09-17T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/42bd46788d5dd8ec/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-morningstar 2024-09-17T13:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/d0f1b22d4e86121f/immunos-therapeutics-ag-raises-us-11m-in-series-c-financing-european-biotechnology 2024-09-17T13:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/38e45fc355acab14/us-fda-approval-total-knee-study-company-announcement-investegate 2024-09-17T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/59aece9a38c9a104/ritedose-is-proud-to-partner-with-verona-pharma-to-deliver-first-in-class-copd-drug 2024-09-17T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/07cef5811acfd111/ohio-state-s-novel-dhodh-inhibitor-enters-first-human-trials-news-medical 2024-09-17T12:27:37+00:00 weekly 0.7 https://trial.medpath.com/news/9be88d5a87cb8da5/glp-1s-can-potentially-cut-cirrhosis-related-complications-in-masld-study-biospace 2024-09-17T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/f74ea8e6fc52a522/leukemia-survivor-breast-cancer-caregiver-why-i-joined-md-anderson-s-boot-walk-to-end 2024-09-17T12:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/299ab0772d73564e/endomimeticstm-awarded-2-8-million-phase-ii-sbir-grant-to-globenewswire 2024-09-17T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/29f0360de5351b32/rosacea-in-patients-of-color-experts-call-for-better-recognition-and-diagnosis 2024-09-17T12:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/3e3a2c3c0c39067a/bridgebio-announces-infigratinib-is-the-first-ever-investigational-therapeutic-option-stock-titan 2024-09-17T11:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/49bd3c261dfde3c9/innovation-driving-cancer-s-solid-tumors-market-aemd-stock-news 2024-09-17T11:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/36336736854bfa55/rocket-pharmaceuticals-announces-completion-of-enrollment-in-phase-2-pivotal-trial-of-rp 2024-09-17T11:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/2c37304ec4a903fa/transcode-therapeutics-announces-first-patients-treated-in-phase-1-clinical-trial-with 2024-09-17T11:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/52884b7ece518fc2/guard-therapeutics-phase-2-results-published-in-leading-scientific-journal-placera 2024-09-17T11:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/e5420fed46a230d9/poseida-therapeutics-p-bcma-allo1-receives-us-fda-rmat-designation-to-treat 2024-09-17T11:30:18+00:00 weekly 0.7 https://trial.medpath.com/news/ac8f037253d3ae6f/beigene-receives-israeli-ministry-of-health-approval-for-tevimbra-r-for-the-treatment-of 2024-09-17T11:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/7265bd3ea2fa3b08/cullinan-therapeutics-receives-approval-to-initiate-its-global-phase-1-clinical-trial-of-cln 2024-09-17T11:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/b52e098ea3455bb6/boston-scientific-receives-fda-approval-for-expanded-indication-of-ingevitytm-pacing 2024-09-17T11:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/f0419b400b7fca3c/synbiotics-in-patients-at-risk-for-spontaneous-preterm-birth-protocol-for-a-multi-centre 2024-09-17T10:33:23+00:00 weekly 0.7 https://trial.medpath.com/news/7d18138b7fd7d5cd/ascletis-enters-the-obesity-drug-space-with-announcement-of-two-ongoing-u-s-phase-i 2024-09-17T10:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/783a92e534dfc414/ferrer-advances-research-into-progressive-supranuclear-palsy-psp-with-the-inclusion-of 2024-09-17T09:57:08+00:00 weekly 0.7 https://trial.medpath.com/news/e488bcf95ee2738a/little-pre-and-postmarket-testing-for-most-recalled-cv-devices-tctmd-com 2024-09-17T09:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/ca1222dc3366dc68/novartis-phase-iii-natalee-trial-of-kisqali-shows-deepening-benefit-in-new-analysis 2024-09-17T09:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/39c71231c7c6aa6f/astrazeneca-s-imfinzi-and-imjudo-found-to-extend-survival-in-liver-cancer-trial 2024-09-17T09:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/89dc17d1f31da15a/combo-treatment-doubles-survival-for-patients-with-advanced-kidney-cancer 2024-09-17T09:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/59dc75f655e1f1d7/pipeline-watch-four-approvals-and-32-phase-iii-readouts-scrip-citeline 2024-09-17T08:38:45+00:00 weekly 0.7 https://trial.medpath.com/news/42345e4bafd25840/minervax-and-wacker-biotech-announce-manufacturing-collaboration-for-prophylactic 2024-09-17T07:31:49+00:00 weekly 0.7 https://trial.medpath.com/news/6ee684204eaadc6d/expert-highlights-critical-role-of-early-diagnosis-and-targeted-therapy-in-bpdcn-management 2024-09-17T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/98d86c34715fc6bb/karolinska-development-s-portfolio-company-anacardio-reports-progress-in-two-clinical 2024-09-17T06:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/ba3a9e9069b11ae0/studies-show-immunotherapy-improves-long-term-survival-in-growing-number-of-cancers 2024-09-17T05:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/d981bceb4a2c909d/mortality-and-functional-outcomes-18-months-after-hospitalization-for-covid-19-in-geriatric-patients 2024-09-17T05:36:39+00:00 weekly 0.7 https://trial.medpath.com/news/0fdeacdb6a531286/ai-powered-data-integration-revolutionizes-drug-diversion-detection-in-healthcare-systems 2024-09-17T05:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/0cb4f68a6950196d/gene-therapy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-17T04:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/d57b6dbc2a2aba4a/spinal-muscular-atrophy-clinical-trials-2024-updated-ema-openpr-com 2024-09-17T04:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/0a9c1b86f29b2f35/lykos-could-see-five-year-delay-in-possible-fda-approval-of-mdma-inside-health-policy 2024-09-17T02:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/f1b7ab09bdbf28e0/fda-issues-draft-guidance-on-conducting-multiregional-clinical-trials-in-oncology 2024-09-17T02:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/6205a05330a9438f/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-17T02:07:19+00:00 weekly 0.7 https://trial.medpath.com/news/5b1b7aff95e44f59/esmo-2024-fecal-microbiota-transplantation-vs-placebo-in-patients-receiving-urotoday 2024-09-17T01:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/250e5cf880e8071b/astrazeneca-s-perioperative-imfinzi-significantly-extends-survival-in-type-of-bladder-cancer 2024-09-17T01:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/60d1f5b87df6e4f7/pharmaust-seeks-european-orphan-drug-designation-for-mnd-als-drug-monepantel 2024-09-17T00:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/6fb65e393102693a/drug-safety-experts-call-for-enhanced-diagnostic-accuracy-in-clinical-trials-to-protect-patient-safety 2024-09-17T00:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/d70fe8ac217a459e/ipf-drug-meets-primary-end-point-managed-healthcare-executive 2024-09-17T00:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/ac9d3c3e3765e713/launch-of-yselty-r-generic-name-linzagolix-for-uterine-fibroid-treatment-in-europe 2024-09-17T00:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/8cf142a11f64f8e1/5-year-analysis-of-phase-iii-himalaya-confirms-survival-benefit-of-stride-in 2024-09-16T22:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/d97faa97c52e6932/fda-approves-manufacturing-line-for-rsv-therapy-becker-s-hospital-review 2024-09-16T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/6e073962fa8b74f7/elderly-monkeys-aged-more-slowly-when-given-a-cheap-diabetes-drug-used-by-millions 2024-09-16T21:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/4f56218767a840a1/darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-urotoday 2024-09-16T21:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/4f80fb16384d4e1e/qu-scientists-in-precision-medicine-breakthrough-gulf-times 2024-09-16T21:08:54+00:00 weekly 0.7 https://trial.medpath.com/news/43e23780f11a52d0/pei-yu-chen-phd-aims-to-create-a-safer-and-more-effective-way-to-deliver-drugs 2024-09-16T21:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/263288da3540131b/phase-2-trial-highlights-potential-of-inavolisib-for-pik3ca-mutated-cancers 2024-09-16T21:03:01+00:00 weekly 0.7 https://trial.medpath.com/news/cebafbb90abe61eb/poor-outcomes-after-tpoxx-mpox-treatment-mainly-seen-in-those-with-weak-immunity 2024-09-16T20:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/b4dcbeda7c3c226b/biotronik-catheter-gets-fda-approval-daic 2024-09-16T20:44:43+00:00 weekly 0.7 https://trial.medpath.com/news/dda6963baf60a583/duke-physician-highlights-positive-ovarian-cancer-clinical-trial-results 2024-09-16T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/304179311fb50635/amg-193-shows-preliminary-clinical-activity-in-mtap-deleted-solid-tumors-onclive 2024-09-16T20:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/51f6c47bf355a55b/brain-metastases-of-her2-positive-breast-cancer-patients-effectively-treated-with-antibody 2024-09-16T20:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/b524fc9d7df8bab2/fda-approves-apple-watch-sleep-apnea-detection-notification-appleinsider 2024-09-16T20:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b38389198c69209/fda-grants-mm-ii-fast-track-designation-for-treatment-of-osteoarthritis-knee-pain 2024-09-16T20:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/f5db3cb6c856b156/fda-drafts-guidance-on-multiregional-clinical-trials-in-oncology-raps 2024-09-16T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/fd89461b88b57dbd/fda-approves-lebrikizumab-for-treatment-of-atopic-dermatitis-pharmacy-times 2024-09-16T19:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/9e73a76b69e137e3/fda-approval-insights-epcoritamab-in-relapsed-refractory-follicular-lymphoma-onclive 2024-09-16T19:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/de18ffb9fd9b3b8a/researchers-announce-clinical-trial-results-for-hard-to-treat-breast-and-bladder-cancers 2024-09-16T19:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/803429652aca8258/regeneron-sny-win-fda-approval-for-a-broader-dupixent-label-yahoo-finance 2024-09-16T19:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/0456261e5cb198d0/newly-initiated-phase-2-breakthrough-trial-to-test-5-ht2c-receptor-agonist-bmb-101 2024-09-16T19:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/c46598b9d2c2bf00/keynote-522-findings-continue-to-shape-the-future-of-tnbc-care-targeted-oncology 2024-09-16T19:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/73c3f09531b5234a/pembrolizumab-improves-outcomes-in-high-risk-bladder-cancer-nci 2024-09-16T18:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/b8cd9a2e71d579d3/techcrunch-minute-fda-approval-sets-the-stage-for-apple-s-airpod-hearing-aids 2024-09-16T18:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/6a5b34d9b7738294/apple-gets-fda-approval-for-smartwatch-sleep-apnea-detection-feature-investopedia 2024-09-16T18:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/318dcd64eae57ae6/tremelimumab-plus-durvalumab-turns-heads-with-updated-five-year-data-in-uhcc 2024-09-16T18:27:31+00:00 weekly 0.7 https://trial.medpath.com/news/f0ec1ef6c1a16989/immunotherapy-and-novel-targeted-drug-appear-beneficial-in-women-with-early-stage 2024-09-16T18:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/b76593ea2d5bd9c4/fda-clears-apple-s-sleep-apnea-detection-feature-for-use-here-s-how-it-works-cnbc 2024-09-16T18:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/70c2e2792a960c7f/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-pharmaceutical-executive 2024-09-16T18:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/9cefb0f417948383/new-eli-lilly-eczema-drug-brings-competition-and-dosing-edge-versus-sanofi-leo-pharma-meds 2024-09-16T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/1c5d28f599daf7a6/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss-benzinga 2024-09-16T17:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/950efad451202721/recon-astrazeneca-releases-positive-results-on-imfinzi-for-bladder-cancer-raps 2024-09-16T17:26:56+00:00 weekly 0.7 https://trial.medpath.com/news/779b4302c2afdc50/fda-approves-biotronik-lead-catheter-for-left-bundle-branch-area-pacing 2024-09-16T17:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/03ce8554c07a2cc2/medical-marijuana-users-see-short-term-gains-in-he-newswise 2024-09-16T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/db674d98294ebdf7/evaxion-reports-convincing-one-year-data-from-phase-2-trial-on-ai-designed-personalized 2024-09-16T17:02:55+00:00 weekly 0.7 https://trial.medpath.com/news/999961f6b2ee875d/rewriting-the-health-care-script-in-africa-c-en-american-chemical-society 2024-09-16T16:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/9635ee7a64243bd9/dr-nicolas-girard-on-luminosity-teliso-v-improves-pros-in-nsclc 2024-09-16T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/7032e60379178c49/dupixent-gains-fda-approval-for-expanded-use-in-adolescents-with-crswnp 2024-09-16T16:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/bcbfcbc9d4badd95/leigh-s-lost-and-found-local-vet-office-takes-part-in-clinical-trial-to-extend-dogs-lives-ky3 2024-09-16T16:42:27+00:00 weekly 0.7 https://trial.medpath.com/news/77d72ca43a6eeff3/fda-approves-new-catheter-system-for-left-bundle-branch-area-pacing-healio 2024-09-16T16:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/cecfb94822a3377d/icmr-signs-agreements-for-first-in-human-clinical-trials-of-four-new-molecules 2024-09-16T16:35:08+00:00 weekly 0.7 https://trial.medpath.com/news/953ca363958c34c0/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T16:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/e6a7add9c3cce26e/inspiremd-submits-carotid-stent-for-fda-premarket-approval-massdevice 2024-09-16T16:28:03+00:00 weekly 0.7 https://trial.medpath.com/news/4863c723273e8cd8/apple-watch-s-sleep-apnea-detection-feature-gets-fda-approval-here-s-how-it-will-work 2024-09-16T16:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/81c6dbf3948607df/pipeline-moves-novo-nordisk-s-liraglutide-scores-in-phase-iii-paediatric-trial 2024-09-16T16:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/06f93dbc6f62e6ed/apple-watch-sleep-apnea-detection-gets-fda-approval-healthleaders-media 2024-09-16T16:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/2bdd3b489bc06a09/fda-lifts-hold-on-zentalis-cancer-drug-trials-investing-com 2024-09-16T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/f33dc7361418ce47/fda-approves-ocrevus-zunovo-for-relapsing-primary-progressive-multiple-sclerosis 2024-09-16T16:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/3e3dc96219b73a37/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win-yahoo 2024-09-16T16:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/efaeef8165c3f32b/fda-approves-first-of-its-kind-cardiac-stent-for-babies-newswise 2024-09-16T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/803c6d759e3226e8/50-years-of-the-cure-celebrating-pioneering-iu-research-and-the-cure-for-testicular-cancer 2024-09-16T16:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/c7f1a5281bfadaaa/splash-177lu-pnt2002-achieves-phase-3-outcomes-for-mcrpc-urology-times 2024-09-16T16:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/9aeb7fb58888399c/immunotherapy-after-surgery-helps-people-with-high-risk-bladder-cancer-live-cancer-free-longer 2024-09-16T15:56:31+00:00 weekly 0.7 https://trial.medpath.com/news/03c32e603abfd033/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-early-stage-triple-negative-breast-cancer 2024-09-16T15:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/324c45183d0a4fe5/imfinzi-plus-imjudo-shows-significant-five-year-survival-improvement-in-unresectable-liver-cancer 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/e9d75e493f68956f/ten-year-data-from-checkmate-067-trial-shows-long-term-survival-benefits-of-opdivo 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/344337f7e7ab98a6/chemo-free-triplet-yields-68-response-rate-in-richter-transformation-medpage-today 2024-09-16T15:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/d5a528c9346d9c01/new-eczema-drug-from-eli-lilly-receives-fda-approval-for-children-and-adults-usa-today 2024-09-16T15:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/9bf0d79bf41e2163/alliance-presents-final-results-from-phase-ii-eurekalert 2024-09-16T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/0eedfd61c97bc108/guru-sonpavde-md-on-phase-3-ambassador-trial-data-in-urothelial-carcinoma 2024-09-16T15:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/e7bb754eacab4182/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc 2024-09-16T15:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/593c7e5bd632ea9a/fda-lifts-partial-clinical-hold-on-trials-evaluating-azenosertib-in-advanced-solid-tumors 2024-09-16T15:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/9b9e3fe2c23fb3da/fda-grants-p-bcma-allo1-rmat-designation-in-r-r-multiple-myeloma 2024-09-16T15:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/28daeca92cec3d7a/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/f51020c19f6e1f51/bayer-targets-expanded-use-approval-for-prostate-cancer-drug-reveals-encouraging 2024-09-16T15:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/f49529b9848a21c1/biotronik-earns-expanded-fda-nod-for-pacing-lead-delivery-catheter-system-massdevice 2024-09-16T15:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/8a9bf2f5793ca886/addressing-disparities-in-food-allergen-immunotherapy-trials-jama-network 2024-09-16T15:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/c4afb79a6246a4e7/first-group-of-healthy-volunteers-dosed-in-qrl-101-mad-study-als-news-today 2024-09-16T15:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/e0622501d3c898a6/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/66a5dda6e9ea5a6a/some-men-with-prostate-cancer-can-benefit-from-immunotherapy 2024-09-16T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/dd3383386d4cbcea/apple-watch-sleep-apnea-detection-gets-fda-clearance-the-verge 2024-09-16T15:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/2a86cced37b73131/weekly-review-dupilumab-lebrikizumab-fda-approved-plus-much-more-contemporary-pediatrics 2024-09-16T15:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/57805efd8f99772c/ozempic-could-curb-progression-of-diabetes-linked-liver-disease 2024-09-16T15:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/b1ab6f76109db7e2/three-apple-watches-get-fda-approval-for-sleep-apnea-detection-from-today-9to5mac 2024-09-16T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/97c2f4614f856109/perioperative-durvalumab-with-neoadjuvant-chemo-boosts-survival-in-cisplatin-eligible-mibc 2024-09-16T15:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/36dba9089d3afd4f/fda-approves-lebrikizumab-for-patients-aged-12-and-older-with-moderate-to-severe 2024-09-16T15:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/91393641be59d2bb/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss 2024-09-16T15:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/ead3a2b0e3853c9a/apac-roundup-cdsco-releases-draft-guidelines-on-good-clinical-practices-for-consultation-raps 2024-09-16T14:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/dbf94448cf6b977f/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free 2024-09-16T14:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/3a610e673e4413aa/positive-trial-demonstrates-safe-breastfeeding-during-endocrine-therapy-break-for-hr-breast-cancer-patients 2024-09-16T14:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/0bde856d7601aaa8/fda-approves-tecentriq-hybreza-cancer-therapy-advisor 2024-09-16T14:47:48+00:00 weekly 0.7 https://trial.medpath.com/news/fc5e404f900acd6c/ocrevus-zunovo-now-approved-in-us-to-treat-relapsing-ms-ppms 2024-09-16T14:44:02+00:00 weekly 0.7 https://trial.medpath.com/news/6ba09f6f71c47df4/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease 2024-09-16T14:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/32b7f6171b88931e/new-trial-to-test-potential-treatment-for-chronic-kidney-disease 2024-09-16T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/c37dc863b6b7b457/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T14:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/b78bbe2ec0d7ba90/novartis-breast-cancer-drug-found-to-cut-disease-recurrence-investopedia 2024-09-16T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/9ca2c5e9c6dfb7ed/risk-for-second-primary-cancer-may-be-no-higher-with-car-t-cell-versus-standard-of-care 2024-09-16T14:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/1203689902470064/sec-form-424b5-filed-by-inmune-bio-inc-quantisnow 2024-09-16T14:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/c54aba0132661307/trishula-therapeutics-presents-positive-results-from-phase-1-trial-of-ttx-030-in-first-line-metastatic-pancreatic-cancer-patients 2024-09-16T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/6f5b95d087b943d4/neoadjuvant-and-adjuvant-pembrolizumab-extends-survival-in-early-stage-tnbc 2024-09-16T14:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/7b46b43b42b8088d/pfizer-drug-treating-fatal-weight-loss-in-cancer-patients-found-effective-investopedia 2024-09-16T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/b225a22efe2534d1/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-clinical-trials-arena 2024-09-16T13:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/41f099353a8947ab/apple-watch-sleep-apnea-detection-gets-fda-approval-techcrunch 2024-09-16T13:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/a49dba0fc689e1c0/esmo-j-j-cues-up-phase-3-for-rybrevant-in-colorectal-cancer-pharmaphorum 2024-09-16T13:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/b706435fb0514393/apple-watch-s-sleep-apnea-notification-feature-granted-fda-approval-tom-s-guide 2024-09-16T13:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/db1c1387d4931c1a/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-yahoo-finance 2024-09-16T13:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/d5a14159fcbacaf2/alliance-unveils-phase-iii-cabozantinib-trial-results-at-esmo-mirage-news 2024-09-16T13:30:47+00:00 weekly 0.7 https://trial.medpath.com/news/702fe87b58e68467/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/d543553384c63e33/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/66233b593face1d5/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T13:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/cd930bd6b985cb9c/pds-biotech-announces-updated-data-from-versatile-002-phase-2-study-in-hnscc 2024-09-16T13:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/73a3ee2d85699872/cvkd-new-blood-thinner-ready-for-phase-3-initiating-coverage-of-cadrenal-therapeutics-inc 2024-09-16T13:24:34+00:00 weekly 0.7 https://trial.medpath.com/news/83ab668128865756/nimmune-biopharma-to-participate-in-ubs-virtual-biotechnology-private-company-symposium 2024-09-16T13:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/af328d3a4071e22f/apple-watch-s-sleep-apnea-detection-feature-receives-fda-approval-macrumors 2024-09-16T13:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/62e415643ba51998/vivtex-enters-new-research-agreement-with-equillium-to-develop-gi-targeted-formulations 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/0b09bd8b2af70051/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/acc505c7af238bee/second-generation-of-i-spy-2-trial-design-is-driving-the-precise-in-precision-medicine 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/45e9cf0cacd40919/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease-new 2024-09-16T13:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/3c0505f94583e09f/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-stock-titan 2024-09-16T13:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/200decdd251b9b74/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/1478abc0b80c8d3c/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-tradingview 2024-09-16T12:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/be51373e6ed13df1/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in-ipsen 2024-09-16T12:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/6def5029efbd5078/don-t-count-out-cipher-pharma-research-capital-says-cantech-letter 2024-09-16T12:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/e23b5dd472209561/gsk-iteos-score-phase-ii-win-for-jemperli-tigit-combo-in-nsclc-biospace 2024-09-16T12:52:21+00:00 weekly 0.7 https://trial.medpath.com/news/ea7c00c440239977/final-results-from-cabinet-phase-iii-trial-reinforce-globenewswire 2024-09-16T12:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/b2273e8361d51bb7/september-16-2024-researchers-examine-feasibility-of-enhanced-tsos-intervention-for 2024-09-16T12:50:17+00:00 weekly 0.7 https://trial.medpath.com/news/fc4a99092562e89d/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in 2024-09-16T12:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/19e90ab798ec7e59/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8 2024-09-16T12:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/fd931915e233bcb8/china-grants-btd-to-blenrep-with-bordex-for-multiple-myeloma 2024-09-16T12:41:07+00:00 weekly 0.7 https://trial.medpath.com/news/4823f8ef8e06fb2d/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T12:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/daf4738a7782904c/mizuho-maintains-neutral-rating-on-apellis-stock-with-steady-price-target-investing-com 2024-09-16T12:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/6208c7a93df9c89a/data-from-a-phase-1-trial-of-highfield-biopharmaceuticals-hf1k16-show-the-new-immuno 2024-09-16T12:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/2f07a194ac9489de/bio-path-holdings-announces-publication-in-biomedicines-biospace 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/1b9a6a49a046401b/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/dd03301f7cea3995/gigapath-ai-model-shows-superior-accuracy-in-predicting-cancer-mutations-and-tumor-burden 2024-09-16T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/6e6b93269b6d977c/novartis-aims-for-single-dose-malaria-cure-with-a-novel-moa-long-acting-aryl-sf5-compound 2024-09-16T12:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/cef18ff100b84acb/roche-s-injectable-pd-l1-inhibitor-granted-fda-approval-for-multiple-cancer-types-pmlive 2024-09-16T12:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/1993ca5af077c494/new-research-highlights-complexities-of-central-centrifugal-cicatricial-alopecia-in-diverse-populations 2024-09-16T12:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/8026139761101d16/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-stock-titan 2024-09-16T12:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/9fc59e5db75be2b0/infex-therapeutics-first-ncfb-patient-dosed-in-resp-x-phase-iia-study-research-tree 2024-09-16T12:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/bce2b63c2985b5be/pds-biotechnology-corporation-announces-updated-results-from-versatile-002-phase 2024-09-16T12:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/a65831d81e70ec8a/phase-iii-aranote-trial-shows-nubeqa-r-darolutamide-significantly-reduced-risk-of 2024-09-16T12:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/a50bf182c1ad469c/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-markets-data 2024-09-16T12:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/006a7238541aca6f/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-placera 2024-09-16T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/7df32d65b642387a/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-markets-insider 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/47a39ea7674774ed/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/6184a341a15d202c/esmo-niagara-backs-imfinzi-in-bladder-cancer-but-will-fda-pharmaphorum 2024-09-16T11:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/350e4cc7a45768a9/inspiremd-seeks-fda-approval-for-carotid-stent-system-investing-com 2024-09-16T11:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/c2300a5a90d1642b/evaxion-reports-promising-phase-2-trial-results-for-cancer-vaccine-investing-com 2024-09-16T11:49:49+00:00 weekly 0.7 https://trial.medpath.com/news/50bf01b938fa417c/medexus-provides-update-on-treosulfan-nda-review-process-and-extended-pdufa-goal-date 2024-09-16T11:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/5275e88561627d10/eli-lilly-announces-fda-approval-for-ebglyss-in-moderate-to-severe-atopic-dermatitis 2024-09-16T11:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/1d2b882256438a5a/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-marketscreener 2024-09-16T11:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/c8d4d39165e8d8d1/biontech-upgraded-by-jp-morgan-with-a-new-price-target-quantisnow 2024-09-16T11:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/6a541c29d9cea7fe/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies 2024-09-16T11:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/6c826f901543ad0d/japan-s-mhlw-approves-csl-arcturus-updated-sa-mrna-covid-19-vaccine-for 2024-09-16T11:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/2bbfe9929147e91f/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress 2024-09-16T11:23:12+00:00 weekly 0.7 https://trial.medpath.com/news/a1e4e0d0b1609767/acrivon-therapeutics-promising-trial-results-and-fda-clearance-tipranks-com 2024-09-16T11:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/3ecaf859f3c3815f/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-stock-titan 2024-09-16T11:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/4dca3bc21bf83986/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-16T11:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/6a69a7c9b169e6ab/pds-biotechnology-announces-updates-data-from-versatile-002-trial-tipranks-com 2024-09-16T11:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/c9f7b6c0df8e2c1a/passage-bio-to-present-positive-interim-data-from-cohort-1-globenewswire 2024-09-16T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/372ea2958b9eb7dd/breakthrough-is-a-game-changer-in-heart-valve-technology-health-tech-world 2024-09-16T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/147673afef07005f/novartis-announces-updated-analysis-from-phase-iii-natalee-trial-tipranks-com 2024-09-16T11:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/4502c802c11066ae/imfinzi-r-durvalumab-plus-imjudo-r-tremelimumab-actl-demonstrated-unprecedented 2024-09-16T11:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/317428ab7a6f70fe/strides-pharma-gets-fda-nod-for-generic-antidepressant-fluoxetine-60-mg-tablet 2024-09-16T11:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/e18ea4f0645b7395/pds-biotech-announces-updated-results-from-versatile-002-globenewswire 2024-09-16T11:02:07+00:00 weekly 0.7 https://trial.medpath.com/news/55c2666b498683ba/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/f205c899afeaf1ac/fda-approves-roche-s-ocrevus-zunovo-with-halozyme-enhanze-delivery-tech 2024-09-16T10:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/4a02cf823aff7234/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T10:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/01399aedbb7ad456/epitomee-surges-200-in-two-days-on-fda-approval-for-weight-loss-pill-ctech 2024-09-16T10:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/f7bf7a369a891558/promising-anti-tumor-activity-and-safety-of-ivonescimab-in-combination-therapies-in-crc 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/21aa999d313bd27b/antennova-releases-latest-data-of-cd73-inhibitor-atn-037-including-a-dcr-of-89-5-in-a 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/08898e4b5f5cec4f/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years 2024-09-16T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/f65a0d89dc8ea89a/pd-1-checkpoint-inhibitor-shows-promise-for-anal-cancer 2024-09-16T10:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/8e4b98c4e85248c3/fda-approval-boosts-weight-loss-pill-co-epitomee-globes-english-glvbs 2024-09-16T10:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/e99c85866853d472/niagara-durvalumab-plus-chemo-improves-efs-and-os-in-cisplatin-eligible-mibc 2024-09-16T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/fe1d993a9067448e/fda-approves-first-otc-hearing-aid-software-pharmaceutical-executive 2024-09-16T10:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/08546978a79e30f7/in-vivo-car-t-cells-move-into-clinical-trials-nature 2024-09-16T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/b8b6712a2cb616e3/certa-therapeutics-announces-international-non-proprietary-name-for-its-first-in-class 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/42695b74a924c87a/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/6f34168e472a4b40/this-drug-shows-promise-in-extending-bladder-cancer-patients-lives-newsbytes 2024-09-16T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/14ce03793c9a0139/dupixent-receives-fda-approval-as-first-crswnp-treatment-pharmaceutical-technology 2024-09-16T09:58:59+00:00 weekly 0.7 https://trial.medpath.com/news/e3461a366878d23a/medsir-presents-new-studies-at-esmo-that-advance-treatment-of-patients-with-poor 2024-09-16T09:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/91bb90b018e05253/deep-behavioural-representation-learning-reveals-risk-profiles-for-malignant-ventricular-arrhythmias 2024-09-16T09:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/f4ad5fa9d652df32/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node 2024-09-16T09:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/b9819cb75fecff06/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-16T09:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/ac3368efffd3f18f/io-biotech-announces-positive-results-from-phase-2-trial-of-io102-io103-in-the-first-line 2024-09-16T09:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/f45e1e50d5e3c5bd/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute-biospace 2024-09-16T09:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/2a7437afe7db5a96/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours 2024-09-16T09:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/c409fe80d642083c/natera-announces-three-new-signatera-publications-includes-groundbreaking-overall 2024-09-16T09:26:06+00:00 weekly 0.7 https://trial.medpath.com/news/3bfd88e6de21f61f/lilly-secures-fda-approval-for-ebglyss-to-treat-atopic-dermatitis 2024-09-16T09:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/a10b6ad132a9ac3d/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours-yahoo-finance 2024-09-16T09:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/32183eef899f7e0e/immunotherapy-drugs-extend-survival-for-patients-with-advanced-melanomas 2024-09-16T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/be95f07e35b4f9aa/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence 2024-09-16T08:49:52+00:00 weekly 0.7 https://trial.medpath.com/news/4172cade88241bbc/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/5c5317fb3ae47ada/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/4f5f586ed3d695d5/fda-approves-tremfya-r-for-ulcerative-colitis-treatment-promising-new-hope-for-patients 2024-09-16T08:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/1221d9876507b51c/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-globenewswire 2024-09-16T08:19:17+00:00 weekly 0.7 https://trial.medpath.com/news/a587fd406322f0cb/gv20-therapeutics-reports-first-clinical-data-for-ai-designed-checkpoint-inhibitor-gv20-0251-in-advanced-solid-tumors 2024-09-16T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/650ae57eec3120ea/diffuse-large-b-cell-lymphoma-is-curable-how-new-drug-polatuzumab-is-working-wonders 2024-09-16T07:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/66d868c923491139/feasibility-and-safety-of-pd-1-blockades-among-elderly-patients-with-p-dove-medical-press 2024-09-16T07:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/944d128975935a2f/fda-finalizes-guidance-on-dose-optimization-for-oncology-therapies-clinical-leader 2024-09-16T07:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/81d2f7bbf6d62cfd/roche-ocrevus-zunovo-approved-by-the-fda-marketscreener 2024-09-16T07:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/aef602d76987be19/lilly-s-ebglyss-gains-approval-for-patients-12-years-and-older 2024-09-16T07:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/39b1750bc239ea7d/esmo-2024-trop2-directed-adcs-show-promise-in-recurrent-gynecological-cancers 2024-09-16T07:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/5463dc6d723d82a4/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T07:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/66db723b5a6d4da1/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteos-s-tigit-in-nsclc 2024-09-16T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/fc78673a79b3aa08/new-survey-reveals-12-of-americans-suffer-from-chronic-insomnia-as-sleep-health-concerns-rise 2024-09-16T07:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/aeb9c71eeb57f8d5/india-formalises-industry-partnerships-for-phase-one-clinical-trials-healthcare-asia 2024-09-16T06:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/dd98c05974a1b66a/bavarian-nordic-s-mpox-vaccine-approved-by-who-medwatch 2024-09-16T06:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/26a91ac0b8ff4b17/exact-sciences-colon-cancer-blood-test-shows-initial-promise-stat-news 2024-09-16T06:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/f78983f5b9dabd04/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pharmacy-times 2024-09-16T06:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/9ad7aea24be83b9a/torl-biotherapeutics-presents-updated-phase-1-results-of-novel-claudin-6-targeted-biospace 2024-09-16T06:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/39ca55decd01b778/esmo-incyte-s-pd-1-treads-new-ground-in-anal-cancer-pharmaphorum 2024-09-16T06:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/bab1fb37b5650f9a/erteilung-des-status-eines-therapiedurchbruchs-fur-sanbexin-sublingualtabletten-durch-die 2024-09-16T06:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/c6bff372ab802739/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/95a95b11823585b1/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/301b1f793b335d19/l-agence-americaine-des-produits-alimentaires-et-medicamenteux-fda-accorde-pr-newswire 2024-09-16T06:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/539c5a68911bb9c0/roche-s-ocrevus-zunovo-gets-fda-approval-to-treat-relapsing-and-progressive 2024-09-16T06:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/4374885c7d479a65/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-as-biospace 2024-09-16T06:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/78e4f629a42a1f27/fda-s-biosimilar-landscape-growing-market-share-and-policy-changes-shape-future-access 2024-09-16T06:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/ce7a804bb56df71c/keynote-006-study-of-pembrolizumab-shows-continued-survival-benefits-in-advanced-melanoma 2024-09-16T06:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/84ea6690e345adc7/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo 2024-09-16T05:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/e3d414a9c3e89827/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T05:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/3abc2991e9bbf5b4/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute 2024-09-16T05:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/168d906c1287fb3f/rybrevant-r-amivantamab-plus-chemotherapy-shows-positive-overall-survival-trend 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/eebc2f2bc69bee91/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/cf9cb03570e28ff7/us-fda-approves-eli-lilly-s-drug-for-eczema-express-pharma 2024-09-16T05:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/eb5cee4b1a9cc3f4/rp1-nivolumab-combo-shows-durable-responses-favorable-safety-in-melanoma 2024-09-16T05:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/e02f263bdb842eb9/association-between-intensive-blood-pressure-lowering-and-stroke-free-survival-among 2024-09-16T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/5e33a7a83684c21b/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s 2024-09-16T04:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/540cb1310a228360/early-data-shows-mrna-4359-may-benefit-patients-with-advanced-solid-cancers 2024-09-16T04:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/65525a164e5b29d9/kura-oncology-inc-latest-stock-news-market-updates 2024-09-16T04:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/f5a68e9087d3c47a/fda-approves-roche-s-tecentriq-hybreza-the-first-and-only-subcutaneous-anti-pd-l-cancer 2024-09-16T04:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/bbb588a02819f3cd/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/bb25fcc1bdfbf131/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/49f2d461a446646a/5-late-stage-mrna-vaccines-to-watch-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/6a1affc465fe6fb7/dimerix-enters-key-collaboration-to-further-boost-action3-trial-recruitment-in-uk 2024-09-16T03:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/92d43a970153b3e8/remarkable-clinical-trial-results-shared-internationally-ansto 2024-09-16T02:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/8719a7ed8a0b2523/clinical-trial-breakthrough-shared-globally-mirage-news 2024-09-16T02:13:09+00:00 weekly 0.7 https://trial.medpath.com/news/c00a30b75993852d/booker-schmitt-paul-king-braun-whitehouse-kennedy-lujan-blumenthal-introduce-the 2024-09-16T01:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/334f47096da3032b/t-dxd-maintains-qol-delays-pain-deterioration-in-hr-her2-low-ultralow-mbc 2024-09-16T01:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/6b78dd9c5ee974a4/digital-support-app-launches-in-uk-to-address-rising-youth-cancer-cases 2024-09-16T01:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/8ad561538a9c78ce/esmo-2024-anlotinib-and-penpulimab-gather-attention-in-hcc-with-apollo-results 2024-09-16T00:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/9b4003bf3d3f3b81/esmo-2024-updates-in-penile-cancer-urotoday 2024-09-16T00:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/701c70fd16ffe13f/who-approves-mpox-vaccine-for-babies-without-clinical-trials-the-conservative-woman 2024-09-16T00:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/4e4e1232a4352299/esmo-2024-dll-3-targeted-therapy-for-neuroendocrine-prostate-cancer-urotoday 2024-09-16T00:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/3f8c15507b2de569/ctdna-based-molecular-residual-disease-and-survival-in 2024-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/86ce2eca454484e0/fda-challenges-abbvie-s-serena-williams-ubrelvy-ad-for-misleading-migraine-claims 2024-09-15T23:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/039f0002bee2b11d/10-year-data-from-checkmate-067-confirms-survival-advantage-of-nivolumab-in-advanced 2024-09-15T23:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/d45674fb188060e1/sintilimab-combined-with-anlotinib-and-chemotherapy-as-second-line-or-later-therapy-in-nature 2024-09-15T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/cb3459710f17c51d/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant 2024-09-15T23:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/fde95af4ca4262d9/fecal-microbiota-transplant-boosts-immunotherapy-in-metastatic-renal-cell-carcinoma-in 2024-09-15T22:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/6665006265832886/azn-imfinzi-regimen-reduces-death-risk-by-25-in-late-stage-muscle-invasive 2024-09-15T22:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/48b2bd803a5aee2e/dupixent-r-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents 2024-09-15T21:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/425ea7b74d7b6251/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-15T21:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/da05f83a10591ced/torl-1-23-generates-responses-in-heavily-pretreated-cldn6-positive-solid-tumors 2024-09-15T21:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/6dbb98c3aa1c60c3/liberty-cupid-study-c-confirms-benefit-of-dupilumab-in-biologic-naive-csu-hcplive 2024-09-15T21:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/4a5194021ba55125/news-from-esmo-an-astrazeneca-win-in-bladder-cancer-and-more 2024-09-15T21:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/3f9e9e64350f4a13/systems-thinking-approach-could-revolutionize-clinical-trial-success-rates 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b69cbc4f0e2c80d5/car-t-cell-therapy-expands-beyond-cancer-new-frontiers-in-autoimmune-disease-treatment 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b4cccd89d03fc7c2/ich-updates-guidelines-ngs-becomes-new-standard-for-viral-safety-testing-in-biotech-manufacturing 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e503d5acda39db19/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival 2024-09-15T20:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/821f4677d2631000/cyramza-plus-lonsurf-did-not-improve-survival-in-metastatic-colorectal-cancer 2024-09-15T20:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/3caf49402938fa12/new-covid-vaccines-may-be-coming-to-australia-here-s-what-to-know-about-the-jn-1-shots 2024-09-15T20:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/59d7efdab675cc29/postsurgical-pembrolizumab-chemotherapy-misses-dfs-goal-in-endometrial-cancer 2024-09-15T20:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/81837c2c7ea016ae/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T20:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/2a96bd444428878f/chemotherapy-de-escalation-associated-with-excellent-hr-her2-breast-cancer-survival 2024-09-15T19:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/a709afa998b435e1/splash-trial-highlights-radiopharmaceutical-lutetium-177-s-role-in-advanced-prostate 2024-09-15T19:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/70c02cd5c6d75551/no-smoking-startup-s-tiny-answer-to-safer-medical-cannabis-nocamels 2024-09-15T19:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/77f300009865150b/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T19:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/5878ee8a4629e358/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study 2024-09-15T19:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/6bf6ea83868c6d21/akeso-published-first-ever-efficacy-data-for-pd-1-vegf-bispecific-antibody-ivonescimab 2024-09-15T19:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/3e6668b85fbd3c4e/recent-health-headlines-fda-approvals-walgreens-settlement-and-more-devdiscourse 2024-09-15T19:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/2fa0e4f23b42b883/retifanlimab-plus-carboplatin-and-paclitaxel-improve-pfs-in-recurrent-metastatic-anal-cancer 2024-09-15T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/e9f0e0a29ddc2c6b/apple-s-airpods-pro-2-revolutionize-hearing-aid-tech-with-fda-approval 2024-09-15T19:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/fb47b5bece4b2f8b/atezolizumab-after-vemurafenib-and-cobimetinib-shows-trend-toward-better-os-in-melanoma 2024-09-15T18:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/b8568700b6501d87/checkmate-77t-highlights-efs-benefit-in-perioperative-nivolumab-in-resectable-nsclc 2024-09-15T18:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/16878bfa890fdb98/icmr-formalises-moas-with-multiple-sponsors-under-phase-one-clinical-trials-network 2024-09-15T18:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/48928b043ff425df/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os 2024-09-15T18:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/7cf9f0e135216b37/extended-follow-up-shows-dfs-benefit-for-pembrolizumab-in-miuc-urology-times 2024-09-15T17:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/6fe343f61f82065b/radiation-therapy-for-women-with-breast-cancer-will-now-last-for-no-more-than-three-weeks 2024-09-15T17:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/cee743eaa59a12d3/missed-out-on-viking-therapeutics-buy-this-weight-loss-biotech-stock-right-now 2024-09-15T17:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/2ae4f8f87cf5dafb/incremental-effectiveness-costs-may-improve-using-biomarker-guided-selection 2024-09-15T17:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/43b2722b67e5dd1b/os-increase-observed-in-neoadjuvant-pembrolizumab-combo-plus-adjuvant-therapy-in-early-tnbc 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/59d1080241d7ba8d/pembrolizumab-combo-shows-dfs-benefit-in-dmmr-endometrial-cancer-subgroup 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/be511cb56d24212d/queen-mary-university-of-london-researchers-announce-ground-breaking-clinical-trial 2024-09-15T17:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/edde06a186f2ca2f/neoadjuvant-pembrolizumab-chemo-adjuvant-pembrolizumab-boosts-os-in-early-tnbc 2024-09-15T17:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/fc5c2ad6193c7cd5/enhanced-progression-free-survival-with-retifanlimab-carboplatin-and-paclitaxel-in 2024-09-15T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/b4197d134a451732/fda-approvals-fraud-settlements-and-global-health-initiatives-latest-health-news 2024-09-15T16:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/bcbb60c64df363a3/doh-6-warns-public-on-unauthorized-mpox-vaccines-daily-guardian 2024-09-15T16:55:56+00:00 weekly 0.7 https://trial.medpath.com/news/ab8933edd8bc2969/researchers-reveal-breakthrough-in-hard-to-treat-cancers-mirage-news 2024-09-15T16:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/02106f07bd9bf11c/queen-mary-university-of-london-researchers-announce-ground-breaking-trial-results-for 2024-09-15T16:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/e2d98516924382f3/long-term-keynote-006-data-support-pembrolizumab-as-soc-in-advanced-melanoma 2024-09-15T16:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/b0edea651d3cf28e/olaparib-cediranib-misses-survival-end-points-in-relapsed-ovarian-cancer-trial-onclive 2024-09-15T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/af6cea4836c66652/j-j-s-tar-200-phase-2b-sunrise-1-study-shows-84-complete-response-in-high-risk 2024-09-15T15:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/17172e9bab013bb4/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases 2024-09-15T15:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/6e4718f9ba154bbf/medilink-presents-yl201-b7h3-adc-at-esmo-2024-with-over-6-months-pfs-in-sclc 2024-09-15T15:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/11d6c30172988bf1/neoadjuvant-immunotherapy-superior-to-targeted-therapy-in-stage-iii-melanoma 2024-09-15T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/fa58db212d4e3693/from-patient-to-entrepreneur-edmond-woman-creates-medical-device-kokh 2024-09-15T14:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/42a57f2b6198ab76/esmo-gsk-iteos-bring-some-optimism-back-to-tigit-pharmaphorum 2024-09-15T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/372e0a3e09373031/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/001efc41d1b3233e/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/4bfce546e0a12e93/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/704530225262b953/esmo-2024-tecentriq-avastin-s-prospects-as-the-first-hcc-adjuvant-therapy-fade 2024-09-15T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/582485cc2ae74298/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-15T14:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/6773e74a2de31684/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/52d92cbdb62aac59/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in 2024-09-15T14:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/3245fb5d3369aa49/prince-trial-highlights-early-detection-of-prostate-cancer-progression-with-psma-pet-ct 2024-09-15T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/eb41219a2ab0c861/disitamab-vedotin-promising-her2-targeted-therapy-for-urothelial-cancer-matthew-galsky 2024-09-15T14:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/36dafebbe0d8cd89/first-cancer-medicine-decision-following-pharmac-funding-boost-scoop-news 2024-09-15T14:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/16ebe6e2f804497f/3d-systems-smith-nephew-announce-fda-clearance-for-total-ankle-replacement-solution 2024-09-15T14:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/8906eddcb8ada22e/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response 2024-09-15T14:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/f9151eda73375323/weekend-icymi-september-9-to-september-13-drug-topics 2024-09-15T14:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/cddb8a27633ba314/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T13:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/b1234215fd101772/dr-angeles-alvarez-secord-on-exciting-responses-with-mirvetuximab-soravtansine-in 2024-09-15T13:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/2204956cfe32eb92/replimune-presents-primary-analysis-data-from-ignyte-globenewswire 2024-09-15T13:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/e469cd8c020664ac/high-dose-vitamin-d3-does-not-provide-benefit-for-metastatic-colorectal-cancer 2024-09-15T13:49:21+00:00 weekly 0.7 https://trial.medpath.com/news/e6f5901b328eb355/ambassador-trial-extended-follow-up-on-adjuvant-pembrolizumab-in-bladder-cancer 2024-09-15T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/3350137b7c488315/scorpion-therapeutics-presents-initial-clinical-data-from-its-phase-1-2-trial-of-stx-478-kxra 2024-09-15T13:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/fa65851018587b67/the-dav132-colon-targeted-adsorbent-does-not-interfere-with-plasma-concentrations-of-nature 2024-09-15T13:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/06d4ee50669b7dc9/who-prequalifies-a-mpox-vaccine-clearing-path-to-access-contagion-live 2024-09-15T13:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/c92bf0fc866082aa/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra 2024-09-15T13:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/7cb00b5ffad7b828/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-morningstar 2024-09-15T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/dfc29b06edaf79aa/oncternal-therapeutics-axes-b-cell-lymphoma-trial-for-car-t-therapy-onct-808 2024-09-15T13:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/1a5f2a41705d3d92/apple-gets-fda-approval-for-airpods-pro-2-hearing-aid-feature-here-is-how-it-can-help-people 2024-09-15T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/e6f9cb8370d16af3/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy-newsroom 2024-09-15T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/news/e5b0ea8ced9bd755/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-stock-titan 2024-09-15T12:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/7fa6868a8dc10e52/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/f494afe21058d11d/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-yahoo-finance 2024-09-15T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/ddfc63a57932dc5e/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/3f90fe1def8a7872/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy 2024-09-15T12:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/a185d96b74a2e45b/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant 2024-09-15T12:52:13+00:00 weekly 0.7 https://trial.medpath.com/news/9a25f17b2dd035ac/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-sustained-overall 2024-09-15T12:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/2b5c3f48e46d54c8/ds-9606-shows-promising-preliminary-clinical-activity-in-patients-with-advanced-solid-tumors 2024-09-15T12:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/b4d533d73e5a2fb1/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-globenewswire 2024-09-15T12:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/47f7003d806667ef/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response 2024-09-15T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/aa08b09b09b9519f/lenvatinib-pembrolizumab-and-tace-demonstrate-significant-progression-free-survival 2024-09-15T11:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/31c532d6159ce4e1/targeted-pulse-quiz-september-15 2024-09-15T11:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/aaac4def31c68e23/khcc-achieves-breakthrough-in-cancer-treatment-using-modified-t-lymphocytes 2024-09-15T10:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/5a5615cb2342fe47/retina-society-2024-advances-in-amd-therapy-highlight-different-mechanisms-of-action-with 2024-09-15T10:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/03a4dd51e04ad81f/precede-biosciences-presents-new-data-at-esmo-2024-globenewswire 2024-09-15T10:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/13c04ac8d62b598d/no-survival-gain-with-preoperative-crt-plus-perioperative-chemo-for-gastric-cancer 2024-09-15T09:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/eee3c0c0fb98f21b/mayo-clinic-pharmacist-advocates-for-evidence-based-cannabis-discussions-in-cancer-care 2024-09-15T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/16b155e9002dbcb5/neoadjuvant-nivolumab-and-relatlimab-in-locally-advanced-mmr-deficient-colon-cancer 2024-09-15T07:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/4db8e1f9d581a893/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and 2024-09-15T07:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/be7ba7e75197c3d8/nhs-chiefs-to-roll-out-new-drugs-for-lethal-lung-disease-that-took-life-of-star-trek-actor 2024-09-15T05:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/9bb1c847401df09c/study-reveals-quality-gap-in-online-psoriasis-treatment-information-sources 2024-09-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/260e7c20bf707b67/retina-society-2024-first-time-phase-2-clinical-trial-results-for-onl-1204-for 2024-09-15T04:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/da7fc50188653d5b/breakthrough-as-scientists-develop-cancer-killing-treatment-that-preserves-healthy-body-cells 2024-09-15T01:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/0371a95ef694ad43/novel-agents-and-promising-combinations-in-urothelial-and-renal-cell-carcinoma-urotoday 2024-09-15T00:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/3edc49928a9cfa4b/clinical-trial-shows-promise-for-maralixibat-in-treating-algs-related-cholestatic-pruritus 2024-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d2d96ec78ac6ce5f/esmo-2024-dr-jonasch-on-implications-of-positive-hif-2a-inhibitor-data-in-ccrcc 2024-09-14T23:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/4c602ea26574320b/real-world-study-shows-comparable-outcomes-between-ct-p13-remicade-in-ra 2024-09-14T23:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/b50f80a58382de26/gan-lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin 2024-09-14T23:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/73e294f3fe899b45/ipilimumab-nivolumab-significantly-improves-12-month-nccrcc-survival-in-sunniforecast 2024-09-14T22:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/ebb66e807bac9c0f/innovative-heart-valve-technology-could-improve-patient-lives-news-medical 2024-09-14T21:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/78ed27b6f2bb1aae/enfortumab-vedotin-effective-in-patients-with-urothelial-cancer-outside-of-clinical-trials 2024-09-14T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/b3519b0eab541cb4/united-states-remote-climate-control-market-by-application-2024-2031-third-eye-news 2024-09-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/740dc11282a49dbf/andrea-banty-np-dnp-navigating-new-developments-in-ibd-therapeutics-hcplive 2024-09-14T21:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/bc94d3cc74290661/cancer-test-firm-oncologica-looking-to-raise-cash-this-is-money 2024-09-14T20:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/58e08003108ee391/retifanlimab-plus-carboplatin-meets-pfs-end-point-in-metastatic-scac-cancer-network 2024-09-14T20:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/1d414322a36cec8a/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc 2024-09-14T20:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/f0001e4092b85fa1/safety-activity-seen-with-frontline-zanidatamab-plus-chemo-bevacizumab-in-her2-mcrc 2024-09-14T20:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/35e23efed9fa27af/diabetes-drug-may-lower-death-rate-in-obese-people-study-the-hindu 2024-09-14T20:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/c1dd813522ce6c41/zipalertinib-shows-promise-in-heavily-pretreated-egfr-exon-20-mutated-nsclc 2024-09-14T19:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/b8781611f2313634/adjuvant-pembrolizumab-chemotherapy-fails-to-improve-dfs-high-risk-endometrial-cancer 2024-09-14T19:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/82eb66a505bb5bca/first-of-its-kind-colorectal-cancer-data-from-prospective-galaxy-study-released-at-esmo 2024-09-14T18:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/ef7bb6b1d8d8902b/encorafenib-binimetinib-exhibits-anti-tumor-activity-in-untreated-braf-mutant-advanced-nsclc 2024-09-14T18:24:44+00:00 weekly 0.7 https://trial.medpath.com/news/530bafbf27cff1c8/neoadjuvant-dato-dxd-plus-durvalumab-shows-variable-pcr-rates-in-stage-ii-iii-breast-cancer 2024-09-14T18:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/844d363c9b16aa22/esmo-2024-invited-discussant-optimizing-post-io-therapy-in-clear-cell-rcc-and 2024-09-14T17:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/1edb397823140a18/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid 2024-09-14T17:26:42+00:00 weekly 0.7 https://trial.medpath.com/news/6aa66b5e2f0b4d5e/first-line-t-dxd-combinations-show-early-antitumor-activity-in-her2-gastric-gej-cancers 2024-09-14T17:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/322f6895af68339e/study-ev-103-dose-escalation-cohort-a-5y-follow-up-of-first-line-enfortumab-vedotin 2024-09-14T16:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/44cfeb409678005c/tigit-drug-from-iteos-shrinks-lung-tumors-in-trial-biopharma-dive 2024-09-14T16:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/da0690e9e6a08ef0/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win-biocentury 2024-09-14T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/2749c44d6d67f179/effect-of-aortic-valve-replacement-on-myocardial-perfusion-and-exercise-capacity-in-patients 2024-09-14T16:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/b9d6f8be1e273986/data-support-pembrolizumab-regimen-as-new-standard-for-advanced-cervical-cancer 2024-09-14T16:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/7e44198d7328aafe/colorado-researcher-says-people-with-ptsd-are-losing-out-on-an-effective-treatment 2024-09-14T16:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/e8d968eac7b58964/bl-b01d1-shows-favorable-phase-2-efficacy-safety-for-urothelial-carcinoma-urology-times 2024-09-14T15:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/b1886e02c168a24f/checkpoint-inhibitor-staves-off-disease-progression-in-anal-cancer-trial-stat-news 2024-09-14T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/a0c1f7ec7c35cd37/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-with 2024-09-14T14:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/57a04e54dbfae508/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of 2024-09-14T14:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/707ddb4f4e005baf/niktimvo-for-the-treatment-of-cgvhd-us-clinical-trials-arena 2024-09-14T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/caf05729d2ecf89f/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-14T13:40:20+00:00 weekly 0.7 https://trial.medpath.com/news/28075c819325f987/company-statement-on-fda-advisory-committee-meeting-biospace 2024-09-14T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/d02a168f5bceb97a/icmr-to-advance-1st-in-human-trials-for-zika-flu-blood-cancer-therapies-health-news 2024-09-14T12:38:54+00:00 weekly 0.7 https://trial.medpath.com/news/0071138d5af6f40d/gut-microbiome-emerges-as-key-player-in-cancer-immunotherapy-response-new-research-shows 2024-09-14T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/d20b997456b0f9cd/maui-derm-np-pa-fall-2024-conference-to-spotlight-latest-advances-in-dermatology-treatment 2024-09-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/761ac42771a41235/dr-jonathan-riess-on-the-potential-of-io102-io103-the-cancer-vaccine-landscape 2024-09-14T11:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/17f1d94bd76bbda3/esmo-2024-new-leadership-and-groundbreaking-developments-in-oncology-research-and-patient-care 2024-09-14T11:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/e31a2c84fba751a3/experts-highlight-new-dermatological-treatments-importance-of-clinical-trial-diversity 2024-09-14T11:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/8ddeb2841d2cfc58/fda-approves-new-alzheimer-s-drug-to-slow-disease-progression-nbc26 2024-09-14T10:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/3670df462646c60b/what-happened-in-optometry-this-week-september-9 2024-09-14T10:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/aed2de727139da67/ocudyne-completes-successful-pilot-study-of-optic-system-ophthalmology-times 2024-09-14T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/349563672757c2ca/correction-to-eli-lilly-gets-fda-approval-for-eczema-treatment-article-morningstar 2024-09-14T10:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/a0f10b066b71efb0/less-toxic-cancer-therapies-for-healthier-lives-featured-research-seattle-children-s 2024-09-14T09:45:52+00:00 weekly 0.7 https://trial.medpath.com/news/4497b1784379c2a8/fda-updates-warning-for-liver-injury-due-to-fezolinetant-contemporary-ob-gyn 2024-09-14T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/f4afd0a754bf539a/nuvation-bio-announces-positive-pooled-data-from-the-pivotal-phase-2-trust-i-marketscreener 2024-09-14T08:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/f4a9c8242851815b/car-t-reduces-all-cause-mortality-greater-than-a-bispecific-antibody-in-mm 2024-09-14T08:09:17+00:00 weekly 0.7 https://trial.medpath.com/news/dfbb7fc6fe29fe0a/immunocore-holdings-plc-american-depositary-shares-imcr-stock-news 2024-09-14T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/c3322294bb1423e3/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-14T07:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/328d824de5fbb133/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-ongoing-acr-368 2024-09-14T07:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/a420765a9bea18b9/neurologylive-r-friday-5-september-13-2024 2024-09-14T07:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/a7a32d6196b9c04c/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-biospace 2024-09-14T06:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/e18e381c9e21bcc1/prelude-therapeutics-smarca2-degrader-prt3789-demonstrated-promising-initial-biospace 2024-09-14T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/news/44da9bcac3413f61/bms-immunotherapy-hits-in-lung-cancer-advancing-to-phase-3-stat-news 2024-09-14T06:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/e3d38d2e536fd36f/oneoncology-cmo-highlights-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-09-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c23bb61fdfac58a/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials 2024-09-14T05:46:41+00:00 weekly 0.7 https://trial.medpath.com/news/9a5c0348917925cb/frontline-bms-986012-plus-nivolumab-chemotherapy-shows-promise-in-es-sclc 2024-09-14T05:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/7562c6f74d05e5f2/nutrition-remains-critical-in-mash-management-despite-new-drug-approval-experts-emphasize 2024-09-14T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a825f1224c40e0a/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-14T00:33:25+00:00 weekly 0.7 https://trial.medpath.com/news/7fb9ff1c391961da/3-biotech-ipos-703m-raised-for-clinical-trials-in-cancer-immunology-endocrine-disorders 2024-09-14T00:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/5e8889c784b5a9ee/japan-s-ministry-of-health-labor-and-welfare-approves-csl-and-arcturus-therapeutics 2024-09-14T00:16:23+00:00 weekly 0.7 https://trial.medpath.com/news/4c27ba5129f0312d/belzutifan-yields-sustained-responses-pfs-in-advanced-clear-cell-rcc-cancer-network 2024-09-14T00:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/1c50549da64525d9/digital-medicine-support-models-tested-for-alcohol-use-disorder 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4226e07e3dc20826/how-to-optimise-treatment-in-egfr-mutant-nsclc 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fdec673f19af6aa0/darolutamide-in-addition-to-adt-versus-adt-in-metastatic-hormone-sensitive-prostate-urotoday 2024-09-13T23:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/57a196bfdf0e27a8/gadgeel-s-preview-of-key-esmo-2024-findings-in-lung-cancer-targeted-oncology 2024-09-13T23:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/c723e7d324bff3ab/adjuvant-durvalumab-fails-to-boost-dfs-in-resected-nsclc-irrespective-of-pd-l1-status 2024-09-13T21:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/152a7f6c8309a0dd/subcutaneous-tecentriq-gets-fda-ok-gilead-shot-succeeds-in-second-hiv-trial 2024-09-13T21:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/4973634bef1e5f74/essa-pharma-presents-updated-phase-1-2-masofaniten-epi-7386-clinical-data-at-the 2024-09-13T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/17f7537da55673cf/beyond-celiac-accelerates-search-for-celiac-disease-cure-by-2030-benzinga 2024-09-13T21:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/ddf1a599f7aa9884/arizona-liver-health-arizona-clinical-trials-celebrates-the-grand-opening-of-act-medical-park 2024-09-13T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/c320b2d539cc18b0/a-pde4b-inhibitor-with-demonstrated-clinical-potential-in-treating-ipf 2024-09-13T20:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/3372b2cb0f7bcdf6/two-organizations-partner-to-develop-research-on-veterinary-device-for-osteoarthitis 2024-09-13T20:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/2bc10dac4ae43089/mercks-irreversible-lsd1-inhibitor-for-mpns 2024-09-13T19:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/dd8866ccece976c0/a-dual-5-ht2a-and-5-ht2c-receptor-inverse-agonist-developed-to-address-the-limitations-of-pimavanserin 2024-09-13T19:51:25+00:00 weekly 0.7 https://trial.medpath.com/news/f55d2701e76bebf6/consolidation-durvalumab-consistently-improves-pfs-os-in-ls-sclc-subgroups 2024-09-13T19:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/e37a5b13ad12aaf7/a-potent-zwitterionic-inhibitor-of-khk 2024-09-13T19:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/324e718ffb2d5093/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-biospace 2024-09-13T19:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/6b93bc2d2ae76495/a-cbd-analogue-and-gpr55-antagonist-for-neuropathic-pain 2024-09-13T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/b4e008db74b23acb/press-releases-friday-sep-13-2024-genentech 2024-09-13T18:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/d64d0af6f71aaa72/cabozantinib-nivolumab-combination-findings-further-inform-rcc-care-onclive 2024-09-13T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/88983e7ed85823ae/esmo-2024-a-new-medically-promising-antibody-conjugate-for-metastatic-breast-cancer 2024-09-13T17:59:38+00:00 weekly 0.7 https://trial.medpath.com/news/39ca323c7ce9e10c/tivozanib-monotherapy-bests-lower-dose-tivozanib-plus-nivolumab-in-metastatic-rcc-onclive 2024-09-13T17:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/9c09feb934a40817/fda-approves-subcutaneous-formulation-of-ocrelizumab-for-relapsing-and-progresive 2024-09-13T17:51:54+00:00 weekly 0.7 https://trial.medpath.com/news/bcf2e5fc32eb77c0/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug-pharmaceutical-technology 2024-09-13T17:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/c3c84352a0215bab/cipher-pharmaceuticals-partner-moberg-pharma-ab-provides-update-on-mob-015-phase-3-study 2024-09-13T17:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/dbc2c56f8aa1efa2/novel-adc-azd8205-demonstrates-manageable-safety-profile-and-preliminary-efficacy-in 2024-09-13T17:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/61722c3518b689aa/inflammatix-raises-57m-to-advance-test-for-infection-sepsis-medtech-dive 2024-09-13T16:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/e4f124a8dc740027/fda-approves-dupilumab-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps 2024-09-13T16:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/1def798875ddd8b2/engineered-parasite-delivers-therapeutic-proteins-to-the-mouse-brain-nature-biotechnology 2024-09-13T16:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/6746085633a9e2df/new-guidance-helps-clinicians-use-pemivibart-to-protect-immunocompromised-patients 2024-09-13T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/b00c4a25025b28d6/lenvatinib-pembrolizumab-combo-shows-promise-in-thymic-epithelial-tumors 2024-09-13T15:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/26376d4114b4f72a/essential-components-of-an-electronic-patient-reported-symptom-monitoring-and-jama-network 2024-09-13T15:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/749a81f6db2d0637/fixed-duration-vs-continuous-cll-therapy-balancing-efficacy-quality-of-life-and-costs 2024-09-13T15:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/695483bbdd5d7250/study-identifies-key-factors-for-long-term-weight-loss-with-glp-1-medications 2024-09-13T15:14:02+00:00 weekly 0.7 https://trial.medpath.com/news/7b3d12b6b9cd58ff/antisense-oligonucleotide-vo659-reduces-mutant-huntingtin-protein-interim-phase-1-2-data-show 2024-09-13T15:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/04e8483ab3228f1d/ozempic-or-saxenda-for-weight-loss-which-works-best 2024-09-13T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/d79023125296480c/astrazeneca-launches-truqap-as-korea-s-1st-akt-inhibitor-for-breast-cancer-patients 2024-09-13T14:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/aae83e9cdd172836/inhaled-antibiotic-for-bronchiectasis-shows-benefit-and-then-it-doesn-t-medpage-today 2024-09-13T14:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/93fde878c4198fd7/endo-presents-data-at-the-american-orthopaedic-foot-ankle-society-annual-meeting 2024-09-13T14:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/c08633202ebbf390/representation-of-women-and-people-of-color-in-clinical-trials-is-crucial 2024-09-13T14:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/6f04f4eb34e0c779/moderna-forecasts-lower-sales-next-year-shares-near-four-year-low-bilyonaryo 2024-09-13T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/79d2b54e43c4bf81/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2 2024-09-13T14:18:33+00:00 weekly 0.7 https://trial.medpath.com/news/8d674c93531a2b7b/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast 2024-09-13T14:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/55abcbaad447a8f7/oshkosh-defense-submits-phase-ii-proposal-for-rcv-program-asdnews 2024-09-13T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/news/d97234ac116f2dc6/fda-roundup-apple-airpods-hearing-aids-tremfya-for-ulcerative-colitis-drug-topics 2024-09-13T13:51:07+00:00 weekly 0.7 https://trial.medpath.com/news/af2a42530fcab31c/esmo-2024-new-hope-in-the-treatment-of-thymus-gland-cancers-gustave-roussy 2024-09-13T13:32:23+00:00 weekly 0.7 https://trial.medpath.com/news/6d77de13e2f0958f/oncology-leaders-highlight-challenges-in-managing-rapidly-evolving-cancer-treatment-data 2024-09-13T13:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/a6f911016e6e51b8/research-extends-hope-for-gastric-cancer-patients-with-peritoneal-metastasis 2024-09-13T13:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/c31c931125cf2da4/can-glp-1-drugs-help-with-type-1-diabetes 2024-09-13T13:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/aa8d580eab902640/new-frontiers-in-technology-ai-use-in-clinical-trial-patient-recruitment-in-health-systems 2024-09-13T13:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/3c18100c41f74f7b/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024 2024-09-13T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/23ff696aa0742195/ascendis-to-present-first-results-from-platinum-resistant-ovarian-cancer-proc-cohort-of 2024-09-13T12:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/9da2cf7b29e825de/marengo-therapeutics-announces-clinical-study-collaboration-with-gilead-pr-newswire 2024-09-13T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/bc9840a08e4e0061/depression-five-million-americans-may-benefit-from-psychedelic-therapy-newsweek 2024-09-13T12:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/594d14f25cebde81/esmo-moderna-s-mrna-solid-tumour-vaccine-shows-early-promise-clinical-trials-arena 2024-09-13T12:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/fd72d1972a91bd82/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-trial-evaluating 2024-09-13T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/5875b61d8cbde639/ira-implementation-reshapes-cancer-drug-development-and-patient-access-landscape 2024-09-13T12:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/3168ce962a6b70f2/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-gsk 2024-09-13T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/172a8da42ac485d5/psychedelic-therapeutics-clinical-trials-research-report-globenewswire 2024-09-13T10:58:33+00:00 weekly 0.7 https://trial.medpath.com/news/d11f9509958e7279/cooperation-across-healthcare-service-levels-for-medication-reviews-in-older-people-with 2024-09-13T10:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/95c8b467a2a70e57/nvo-with-obesity-drug-demand-surging-is-novo-nordisk-a-buy-stocknews 2024-09-13T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/83817baef6d9fb82/better-quicker-and-more-effective-treatment-for-patients-with-sepsis 2024-09-13T10:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/48eca84e42989ff9/ozempic-mounjaro-help-people-with-type-1-diabetes-control-blood-sugar-lose-weight 2024-09-13T10:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/0f8ca1f04f9746d4/trial-of-67cu-sar-bispsma-in-mcrpc-progresses-through-multi-dose-cohort 2024-09-13T10:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/ebf31987c134f216/who-prequalifies-the-first-vaccine-against-mpox 2024-09-13T09:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/f81d7f1a70402a16/us-fda-approves-injectable-version-of-roche-s-multiple-sclerosis-therapy-wtvb-1590-am 2024-09-13T09:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/ef904fa0f6c47727/pharmacovigilance-study-of-the-association-between-peripheral-neuropathy-and-antibody-nature 2024-09-13T08:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/feef8a7fe6436141/nordic-clinical-trials-conference-to-address-key-industry-challenges-and-innovation-in-copenhagen 2024-09-13T08:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/2da9f48e4587cc56/sjpedpanel-a-pan-cancer-gene-panel-for-childhood-malignancies-to-enhance-aacr-journals 2024-09-13T08:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/2ee413d5f692d4f1/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to 2024-09-13T08:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/0123140234d6d941/nxera-s-partner-cancer-research-uk-to-present-on-phase-1-2a-clinical-trial-with-biospace 2024-09-13T07:54:41+00:00 weekly 0.7 https://trial.medpath.com/news/8c9890a5d0914ae4/stapokibart-was-granted-marketing-approval-from-national-medical-products-biospace 2024-09-13T07:42:25+00:00 weekly 0.7 https://trial.medpath.com/news/a7d1d2a91991c667/nkgen-biotech-s-positive-phase-1-clinical-data-in-moderate-alzheimer-s-disease-advances 2024-09-13T07:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/2988a6f6a113dc4f/moberg-pharma-ab-receives-information-about-clinical-cure-in-a-subset-of-patients-in-the 2024-09-13T07:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/f69c733de3cf7c7d/world-sepsis-day-highlights-critical-need-for-better-trial-design-and-targeted-therapeutics 2024-09-13T06:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/9a200b276dd4d041/international-research-team-proposes-multimodal-treatment-strategy-for-long-covid-and-post-acute-infectious-syndromes 2024-09-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/5706b7d3c858d81a/two-more-new-drugs-approved-under-1-mechanism 2024-09-13T05:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/bb9f816a7b22c50c/increased-antimicrobial-use-precedes-b-cell-cancer-diagnosis-by-up-to-a-decade-danish-study-reveals 2024-09-13T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/3849b52d25ebd840/research-seeks-to-leverage-ai-behavioral-data-to-improve-mental-health 2024-09-13T04:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/55742a9039c9b7c3/less-toxic-more-personalized-treatments-on-the-horizon-in-her2-breast-cancer 2024-09-13T04:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/07b299cbb96cf79d/investigator-initiated-clinical-studies-to-be-launched-following-confirmation-of-tumor 2024-09-13T03:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/58ad5c5b265c4b57/fda-denies-accelerated-approval-path-for-moderna-merck-s-ai-driven-melanoma-vaccine 2024-09-13T03:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/a3fe6af6d85e4623/moderna-scales-back-rsv-ambitions-cuts-pipeline-programs-amid-market-challenges 2024-09-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aeec6ddef386928a/halozyme-announces-fda-approval-of-roche-s-tecentriq-hybrezatm-with-enhanze-r-for 2024-09-13T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/news/89874e07f90dea4d/equitable-breakthroughs-in-medicine-development-eqbmed-to-work-with-inaugural 2024-09-13T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/533ccaf28e1e406e/fda-approves-lilly-s-ebglyss-lebrikizumab-for-atopic-dermatitis 2024-09-13T00:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/fb6140914ff7d3e5/telitacicept-shows-promise-as-alternative-treatment-for-iga-nephropathy-in-real-world-study 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/85b4926012724a19/ai-technology-revolutionizes-pharmaceutical-supply-chain-management-to-combat-drug-shortages 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d600c036f63ba4e6/fda-approves-subcutaneous-atezolizumab-and-hyaluronidase-tqjs-for-use-in-all-onclive 2024-09-12T22:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/977f5a9f8bb163cf/gilead-s-twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and 2024-09-12T22:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/51b4cfb4c3a8dfac/cvrx-touts-positive-two-year-data-for-heart-failure-neuromodulation-device 2024-09-12T22:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/074386f7bad4beb1/neurocrine-biosciences-provides-update-on-eruditetm-phase-2-data-for-luvadaxistat-in 2024-09-12T21:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/13588cdec9149122/alio-launches-calibration-and-validation-cava-study-to-expand-alio-platform-s-fda-biospace 2024-09-12T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/ca3e7ac8b789483e/immuneering-announces-positive-initial-phase-2a-data 2024-09-12T21:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/2ecaabc835814b61/bridgebio-grows-up-trims-pipeline-as-it-leans-into-late-stage-assets-biospace 2024-09-12T20:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/83348f660e9b9c28/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2025-financial-results 2024-09-12T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/1b7e4f0317f14d53/zambon-announces-publication-of-phase-3-promis-i-and-ii-study-results-in-the-lancet 2024-09-12T20:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/4714f86172c08426/association-of-statin-metformin-and-aspirin-use-with-hepatocellular-carcinoma-in-the-all-of 2024-09-12T18:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/c1f79bf31f6b01ed/cancer-stage-vs-mortality-end-points-in-randomized-clinical-trials-of-cancer-screening 2024-09-12T17:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/9d0d45fbb539084a/spark-biomedical-awarded-national-institute-on-drug-abuse-funding-to-develop-ai-morningstar 2024-09-12T17:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/d6b4c5a93b938f74/digital-twin-technology-may-serve-as-soc-control-in-gvhd-trial-targeted-oncology 2024-09-12T17:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/ec8fea31f4d537a1/omrx-oncology-launches-to-advance-investigational-oral-checkpoint-inhibitor-designed-to 2024-09-12T17:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/77e50379b11d850e/sansum-diabetes-research-institute-is-actively-recruiting-patients-for-pediatric-clinical-trials 2024-09-12T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/e0a3031a340661d7/oxford-heartbeat-completes-patient-recruitment-in-trial-evaluating-presize-neurovascular-software 2024-09-12T17:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/a695d3fc2bbf8dbb/use-of-21-valent-pneumococcal-conjugate-vaccine-among-u-s-adults-cdc 2024-09-12T17:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/668162b67106f383/tumor-induced-b-cell-changes-reveal-potential-biomarker-for-treatment-response-in-triple 2024-09-12T16:25:31+00:00 weekly 0.7 https://trial.medpath.com/news/8f1aca6d6c9131ab/fda-gives-authorization-for-first-over-the-counter-hearing-aid-software-device-hcplive 2024-09-12T16:23:23+00:00 weekly 0.7 https://trial.medpath.com/news/be85287781a1d47f/yunu-extends-free-cancer-center-use-of-platform-for-all-children-s-oncology-group-clinical-trials 2024-09-12T15:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/9a4c138702a28bfb/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna 2024-09-12T15:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/da079c8233e55f6e/medtronic-scores-fda-approvals-for-several-new-therapies-to-drive-sales-star-tribune 2024-09-12T15:37:04+00:00 weekly 0.7 https://trial.medpath.com/news/9b8e3518b142f6c5/shorter-course-radiation-better-option-for-breast-cancer-patients-than-conventional-schedule 2024-09-12T15:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/39b466ca2fdce4b9/vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3 2024-09-12T15:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/6529062044dbb41e/richmond-clinical-trials-seeks-volunteers-for-vaccine-studies 2024-09-12T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/5d74d57ee99ae9d0/three-biotech-firms-secure-700m-in-major-ipo-wave-signaling-market-momentum 2024-09-12T15:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/8280c311bb9a6be1/fda-approves-arthroscopic-knee-cartilage-repair-orthopedics-this-week 2024-09-12T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/news/50dd26f939bb490b/trimodal-therapy-promising-for-recurrent-high-grade-t1-bladder-cancer 2024-09-12T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/f6fa37d3f9bd1075/an-injectable-hiv-prevention-drug-is-highly-effective-but-wildly-expensive 2024-09-12T14:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/73e422a409e268d4/matinee-mepolizumab-significantly-reduces-copd-exacerbations-pulmonology-advisor 2024-09-12T13:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/0005e3323562a770/easd-2024-hightide-therapeutics-presents-oral-reports-of-phase-2-studies-highlighting 2024-09-12T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/news/288d08501e150cb1/tcbp-announces-first-patient-completed-the-full-fose-regimen-in-achieve-clinical-trial 2024-09-12T13:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/42256d097c076c1b/high-adderall-dose-linked-to-alarming-risk-of-mental-health-episodes 2024-09-12T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/31737e460f7bae83/f2g-raises-100m-to-bring-antifungal-drug-back-to-fda-biopharma-dive 2024-09-12T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/news/dc4cf1825e689df4/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-pr-newswire 2024-09-12T12:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/8947695c9eb1eef6/alzheimer-s-clinical-trials-face-critical-diversity-challenge-experts-call-for-inclusive-enrollment 2024-09-12T12:23:40+00:00 weekly 0.7 https://trial.medpath.com/news/4549c67824c613b5/sernova-announces-new-positive-data-from-phase-i-ii-trial-regarding-islet-survival-and-function 2024-09-12T12:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/955105ce603a1668/sinopia-secures-phase-ii-sbir-grant-from-the-national-institute-of-dental-and-craniofacial 2024-09-12T12:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/4aded108b481e1ea/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme 2024-09-12T12:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/8e87ed2160363ee3/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101 2024-09-12T12:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/2c6e1568b60c4fc7/vironexis-biotherapeutics-launches-with-fda-clearance-of-ind-application-for-first-ever 2024-09-12T11:49:40+00:00 weekly 0.7 https://trial.medpath.com/news/e72b1168bbc621ca/summit-therapeutics-raises-235m-for-cancer-drug-trials-tipranks-com 2024-09-12T11:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/d3e33f804ea5803a/world-first-florey-research-aims-to-rapidly-and-accurately-screen-drugs-to-treat-mnd 2024-09-12T11:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/651216fdd684ba33/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of 2024-09-12T11:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/7dcd44bf41222672/comparable-disease-activity-drug-persistence-in-patients-with-jia-who-switch-to-biosimilars 2024-09-12T11:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/a18b315a877aa1ac/positive-phase-ii-bolsters-aura-bioscience-s-confidence-in-vdc-based-therapy-for-ocular 2024-09-12T10:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/5101eb8e2a9f078b/moderna-slashes-research-spending-trims-pipeline-as-it-looks-to-regain-footing-morningstar 2024-09-12T10:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/595e9f72d6e5f5d8/weight-loss-drug-zepbound-may-work-better-in-women-than-men-healthday 2024-09-12T10:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/5ee206977cd7d97a/key-paediatric-milestone-reached-in-dimerix-s-kidney-disease-drug-trial-stockhead 2024-09-12T09:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/ed8b31c2c9af94ed/doherty-clinical-trials-to-conduct-trial-of-australian-developed-needle-free-vaccine-for-avian 2024-09-12T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/38d208c2795212c5/fda-grants-breakthrough-therapy-designation-to-neuraptive-s-ntx-001 2024-09-12T09:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/3a3335299eac92d4/alzheimer-s-drugs-may-work-in-whole-new-way-study-finds 2024-09-12T09:09:03+00:00 weekly 0.7 https://trial.medpath.com/news/7f086d843fad45cc/crispr-fixes-multiple-dystrophin-duplications-in-dmd-patient-cells 2024-09-12T09:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/c2ef6f4172dde5a7/pbm-transparency-crisis-industry-expert-calls-for-reform-to-improve-drug-access-and-pricing 2024-09-12T08:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc7583ff6786208a/cd137-antibodies-clinical-trials-market-opportunity-yahoo-finance 2024-09-12T08:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/fb1dfbe2bdeeb7f5/september-12-2024-nih-collaboratory-biostatisticians-evaluate-analytic-models-for 2024-09-12T08:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/7cbf2b2ca99c6372/ryvu-therapeutics-reports-2024-half-year-financial-results-and-provides-corporate-update 2024-09-12T08:03:40+00:00 weekly 0.7 https://trial.medpath.com/news/16ab8b8165956b79/novotech-publishes-report-on-research-into-endometrial-cancer-a-leading-cause-of-massbio 2024-09-12T06:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/431e56ac8a34a9e2/novotech-report-analyses-epilepsy-research-trends-finding-more-than-4000-clinical-massbio 2024-09-12T06:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/5cbaf2c44e3c5718/novotech-liver-cancer-research-landscape-report-finds-1700-trials-initiated-globally 2024-09-12T06:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/6f3ca8dac51c1cb1/new-report-highlights-global-trends-and-advances-in-chronic-lymphocytic-leukemia-massbio 2024-09-12T06:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/dd98e06b3770055b/bmi-s-relation-to-cancer-therapy-mortality-risks-not-so-straightforward-eurekalert 2024-09-12T05:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/bd70bbea76a89516/innate-pharma-reports-first-half-2024-business-update-and-financial-results-morningstar 2024-09-12T05:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/ef0b470f716a3d87/press-release-sanofi-radiomedix-and-orano-med-announce-licensing-agreement-on-next 2024-09-12T05:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/5497e99bee3caeb2/new-treatment-option-for-graves-disease-finally-on-the-horizon 2024-09-12T05:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/5305738733f0306a/in-depth-report-on-global-oesophageal-cancer-clinical-trials-now-available-massbio 2024-09-12T04:47:43+00:00 weekly 0.7 https://trial.medpath.com/news/518fa1e530cbfe8e/alx-oncology-s-evorpacept-gains-momentum-with-fda-fast-track-designations 2024-09-12T02:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/31db52acc8a13423/clinical-development-of-gamma-delta-t-cell-therapy-inb-400-paused-in-glioblastoma 2024-09-12T02:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/5627c43df2d5b70e/multimodal-analgesia-approach-in-acute-low-back-pain-management-a-phase-iii-study-of 2024-09-12T02:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/962fda2778084aaa/two-stage-screening-for-obstructive-sleep-apnea-in-the-primary-practice-setting 2024-09-12T02:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/0df5c168ade66e0c/matregenix-awarded-three-phase-ii-sbir-and-sttr-contracts-from-the-department-of-the-air-force 2024-09-12T00:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/5bac2ead691dabb7/kintara-therapeutics-provides-update-on-corporate-developments-and-rem-001-clinical-study 2024-09-12T00:31:16+00:00 weekly 0.7 https://trial.medpath.com/news/239d84e1632241e1/global-research-community-applies-covid-19-lessons-to-combat-african-mpox-emergency 2024-09-12T00:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/b8dd44a7a7b0348d/is-the-hype-about-a-new-non-opioid-analgesic-justified-pain-news-network 2024-09-12T00:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/9afa7d8cb1431bc5/hydroxychloroquine-provides-moderate-covid-19-prevention-large 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fafbcd3e89b9f532/clinical-effectiveness-safety-and-compliance-of-two 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/595deeee114850a7/easd-2024-survodutide-shows-promise-in-overweight-obesity-and-mash 2024-09-11T23:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/3d9eb87171dadfca/a-phase-ii-study-of-neoadjuvant-nivolumab-and-nab-paclitaxel-followed-by-urotoday 2024-09-11T23:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/0583bd0a717503ff/the-foundation-for-the-national-institutes-of-health-announces-study-results-published-in-fnih 2024-09-11T22:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/b7cfc7ea0504d342/phase-3-trial-shows-superior-survival-with-rilertinib-for-egfr-mutated-nsclc 2024-09-11T22:29:44+00:00 weekly 0.7 https://trial.medpath.com/news/b15c511f3ed52ed4/tremfya-r-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-pr-newswire 2024-09-11T22:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/4b80ffbd8b0b9f2d/ascendis-pharma-receives-orphan-drug-exclusivity-in-the-u-s-for-yorvipath-morningstar 2024-09-11T22:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/bab25d4569bb348b/conventional-complementary-and-integrative-pain-therapies-in-a-military-population-with 2024-09-11T21:46:42+00:00 weekly 0.7 https://trial.medpath.com/news/cf589db5531151cf/fda-clears-brain-mapping-tool-for-neuromodulation-therapies-parkinson-s-news-today 2024-09-11T21:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/2161799ea7c6fac1/triluminate-update-teer-with-abbott-s-triclip-device-still-safe-effective-after-3-years 2024-09-11T21:13:59+00:00 weekly 0.7 https://trial.medpath.com/news/469b5660ea9d57c3/norton-cancer-institute-patient-receives-first-in-world-clinical-trial-medicine-dos-louisville 2024-09-11T20:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/0b90e1dbebae759a/studies-show-safety-efficacy-of-rsv-preventive-drug-in-kids-cidrap 2024-09-11T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/0c8ae9daf40eea92/biopharma-company-sues-dea-for-unjustified-delays-in-approving-cannabis-research 2024-09-11T20:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/48d5892a8fe808c3/dr-danilov-on-ongoing-mcl-clinical-trials-onclive 2024-09-11T19:57:41+00:00 weekly 0.7 https://trial.medpath.com/news/c881663f6521801e/expanding-possibilities-dana-farber-cancer-institute 2024-09-11T19:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/46a2b02ce9a61a36/fda-reviewers-skeptical-of-ocaliva-for-rare-bile-duct-disease-medpage-today 2024-09-11T19:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/279e02eaf9124660/dedicated-trialist-nurse-navigators-help-advance-cancer-therapy-into-accelerated-approval 2024-09-11T19:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/4f33a43685a6d5b4/fda-grants-510-k-clearance-to-under-mattress-device-that-assists-in-osa-diagnosis-healio 2024-09-11T19:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/78240e6aeb64563b/eortc-extends-medidata-partnership-to-help-power-new-phase-of-oncology-research 2024-09-11T18:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/98fb8b03e5d5ae29/bria-imt-plus-checkpoint-inhibition-maintains-favorable-os-in-metastatic-breast-cancer 2024-09-11T18:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/cc4fafc2f66a8d13/obesity-key-pipeline-developments-and-clinical-trial-insights-iqvia 2024-09-11T18:39:13+00:00 weekly 0.7 https://trial.medpath.com/news/9bff18ed4b62c237/mounjaro-expanded-to-include-weight-management-racgp 2024-09-11T18:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/e1e59753196cc3f8/basking-biosciences-doses-first-subject-in-phase-ii-acute-ischaemic-stroke-trial 2024-09-11T17:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/6aa2e7a58d8806c9/incendia-enrols-first-subject-in-phase-ic-advanced-solid-tumour-trial 2024-09-11T17:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/8ffbd9b9cb691da9/china-boosts-regulatory-framework-for-local-pharmaceutical-manufacturing 2024-09-11T17:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/27132477558b333d/akebia-readies-launch-of-anemia-drug-vafseo-planning-talks-with-fda-on-pre-dialysis-use 2024-09-11T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/04b7bd7c87938c1a/a-new-fentanyl-vaccine-looks-promising-but-treating-drug-addiction-needs-a-more-complex 2024-09-11T16:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/451ad8414f267de8/eu-clinical-trial-regulation-what-does-it-aim-to-achieve 2024-09-11T16:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/852b6be954e562c6/culturally-adapted-lifestyle-intervention-for-south-asian-adults-with-cardiovascular-risk-factors 2024-09-11T16:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/5c010f9fab14b9a8/diabetes-drug-helps-the-immune-system-recognize-reservoirs-of-hiv-study-discovers 2024-09-11T16:12:54+00:00 weekly 0.7 https://trial.medpath.com/news/55293f5d1764b248/veligrotug-for-treatment-of-thyroid-eye-disease-meets-endpoints-in-phase-3-trial-healio 2024-09-11T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/4cb089484403457b/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue 2024-09-11T15:51:03+00:00 weekly 0.7 https://trial.medpath.com/news/8b6a8c0d4a0b1bd5/vla1553-chikungunya-virus-vaccine-shows-antibody-persistence-up-to-2-years-following 2024-09-11T15:47:14+00:00 weekly 0.7 https://trial.medpath.com/news/4470ea4502770403/vaxxas-initiates-phase-i-clinical-trial-of-pre-pandemic-avian-influenza-a-virus-h7n9-biospace 2024-09-11T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/0050766b772efee2/ultimovacs-announces-patient-recruitment-discontinuation-in-globenewswire 2024-09-11T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/5c09d6dbed55c59a/blood-cell-counts-have-unfairly-kept-black-and-middle-eastern-people-from-clinical-trials-study-says 2024-09-11T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/069ed16cc054c4ca/vertex-crispr-s-casgevy-faces-complex-path-to-profitability-biospace 2024-09-11T15:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/06791ee8e5952d6d/adapt-a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-uab 2024-09-11T15:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/0f48e325ef874097/johnson-johnson-reports-data-from-phase-ii-nsclc-treatment-trial-clinical-trials-arena 2024-09-11T14:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/eb728048e75ae815/sotatercept-gains-european-approval-for-pah-for-use-with-other-treatments 2024-09-11T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/4109b27cf1eff8cc/merck-announces-positive-top-line-results-from-phase-3-trial-evaluating-efficacy-and 2024-09-11T14:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/f1e47af4615463b7/entero-signs-letter-of-intent-to-license-and-commercialize-remote-patient-and-machine-vision 2024-09-11T14:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/c3e37d585424954d/dcgi-suspends-entod-s-marketing-approval-for-presvu-eye-drops-amid-misuse-concerns 2024-09-11T14:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/2a0f00c06041be58/indies-pharma-gets-fda-approval-on-new-drug-jamaica-observer 2024-09-11T14:13:26+00:00 weekly 0.7 https://trial.medpath.com/news/c4492edb0be2702c/real-world-data-support-use-of-rpfviii-for-acquired-hemophilia-a-hcplive 2024-09-11T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/264211a8c593c9af/sarepta-s-like-a-curse-on-me-fda-commissioner-califf-says-stat-news 2024-09-11T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/083626f09ce1a468/mhra-authorization-of-dupixent-dupilumab-marks-a-significant-step-forward-as-the-uk 2024-09-11T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/news/6f29a5b0d44faba9/tusamitamab-ravtansine-misses-survival-end-points-in-advanced-nsclc-trial-onclive 2024-09-11T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/26c24e5b96a8b678/pathologists-call-for-reform-in-her2-testing-standards-as-breast-cancer-treatment-landscape-evolves 2024-09-11T13:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/ac1571c30b054dcb/enterprise-therapeutics-appoints-annabella-amatulli-as-head-of-regulatory-affairs 2024-09-11T13:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/8442c9912385d648/improving-lung-cancer-clinical-trial-design-tech-can-help-but-relationships-are-key 2024-09-11T13:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/8822f3496ba3b469/pharmala-to-supply-johns-hopkins-medicine-for-clinical-trial-globenewswire 2024-09-11T13:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/dd5338aa7b749b84/fda-gives-approval-for-duchenne-muscular-dystrophy-pediatric-treatment-science-2-0 2024-09-11T13:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/f8f5d14c552e89d0/theradaptive-announces-first-patient-treated-in-oasis-clinical-trial-of 2024-09-11T13:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/67a0e3a1fe592933/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024 2024-09-11T12:43:38+00:00 weekly 0.7 https://trial.medpath.com/news/e6412c0952a288c9/painreform-ltd-confirms-sutures-compatibility-in-human-clinical-trials-for-prf-110 2024-09-11T12:40:22+00:00 weekly 0.7 https://trial.medpath.com/news/1cae5e192113b2ee/ss-innovations-conducts-interactive-meeting-with-the-center-for-devices-and-yahoo-finance 2024-09-11T12:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/b6e19f3e778bfbd3/allergan-aesthetics-launches-botox-r-cosmetic-onabotulinumtoxina-for-masseter 2024-09-11T12:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/594c67bbccb9df5d/nuance-pharma-completes-recruitment-for-enhance-china-the-phase-3-clinical-trial-of 2024-09-11T12:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/86f8327e620c4fdb/bio-thera-solutions-and-biogen-publish-phase-3-clinical-trial-data-for-tofidence 2024-09-11T12:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/5f19bc3140630aa7/b-riley-raises-viridian-therapeutics-shares-target-on-phase-iii-thrive-study-investing-com 2024-09-11T11:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/da0270fb47f3667c/searching-for-a-vaccine-against-east-coast-fever-tu-braunschweig-blogs 2024-09-11T11:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/9b6ebac2250f7e39/agios-announces-fda-orphan-drug-designation-granted-to-tebapivat-ag-946-for-stock-titan 2024-09-11T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/7d9df273dc9c39f2/sanofi-and-regeneron-s-dupixent-succeeds-in-trial-of-chronic-hives-stat-news 2024-09-11T11:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/2b39a3afe0c5736d/viridian-therapeutics-stock-jumps-after-phase-iii-trial-met-all-endpoints-yahoo-finance 2024-09-11T10:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/9b8ab96209b984a2/arch-biopartners-announces-alberta-health-services-approval-to-proceed-with-phase-ii-trial 2024-09-11T10:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/83146ea572770ded/patient-insights-into-the-decentralisation-of-clinical-trials-european-pharmaceutical-review 2024-09-11T10:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/2585246d136637e5/fda-rejects-mdma-treatment-for-ptsd-setbacks-and-new-directions-lexology 2024-09-11T10:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/f4621b9ea2576d7b/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-triple-class-exposed-nature 2024-09-11T10:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/4305cbc310086166/praxis-stock-poised-for-growth-after-key-pipeline-progress-analyst-says-investing-com 2024-09-11T09:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/dd780001e13dad78/car-t-therapy-won-t-raise-odds-for-a-second-cancer-study-finds 2024-09-11T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/news/67ae5031bff4d66b/daily-pill-helps-people-lose-weight-combines-glp-1-with-other-drug 2024-09-11T09:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/851ad3584b4aba25/blood-test-could-gauge-your-odds-for-lung-trouble-like-copd 2024-09-11T09:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/ce6e6ec8b749b851/sec-form-10-q-filed-by-engene-holdings-inc-quantisnow 2024-09-11T08:52:33+00:00 weekly 0.7 https://trial.medpath.com/news/36bde9a3d9700648/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects 2024-09-11T08:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/ac28f02d706a2239/september-11-2024-harmonie-and-a-new-approach-to-commercial-clinical-trials-in 2024-09-11T08:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/a3cae3e4c37e1e64/never-give-up-treatment-breakthroughs-arrive-for-sclc-cure-today 2024-09-11T07:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/971271061cec083b/radiprodil-significantly-reduces-seizure-frequency-in-phase-1b-honeycomb-study-of 2024-09-11T07:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/e7a77ca9a5d71279/gsk-provides-update-on-phase-i-ii-therapeutic-herpes-simplex-virus-hsv-vaccine-trial 2024-09-11T06:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/b424bee394ac6d44/healthcare-discrimination-study-reveals-multiple-barriers-for-sickle-cell-disease-patients 2024-09-11T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9253cfe4359e422b/bioversys-announces-strategic-investment-from-gibf2-and-launch-of-bv100-clinical 2024-09-11T05:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/d3eba49052a67203/press-release-dupixent-is-the-first-and-only-biologic-to-achieve-significant-improvements-in 2024-09-11T05:46:44+00:00 weekly 0.7 https://trial.medpath.com/news/d86f1747458c0825/study-links-anti-ttg-and-ema-antibodies-to-fibromyalgia-risk-in-celiac-disease-patients 2024-09-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6477c0546efdcfe/piflufolastat-18f-enters-commercial-market-in-spain-urology-times 2024-09-11T04:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/d052c359cfd4e9cd/investors-are-waking-up-to-centessa-s-sleepiness-drug-biopharma-dive 2024-09-11T04:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/a075b6642935be07/expert-reaction-to-conference-abstract-from-a-phase-1-study-on-safety-tolerability-and-weight 2024-09-11T04:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/9601322113f5d0e9/study-reveals-significant-understaging-in-early-stage-pancreatic-cancer-diagnosis 2024-09-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ea1384e36f281a9/roche-not-alarmed-by-obesity-drug-s-side-effects-r-d-head-says-swi-swissinfo-ch 2024-09-11T03:55:39+00:00 weekly 0.7 https://trial.medpath.com/news/68377743889ade8c/a-novo-nordisk-weight-loss-drug-lowers-bmi-in-kids-as-young-as-6-nbc-news 2024-09-11T02:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/c42bf65ae0f66883/novo-nordisk-experimental-obesity-pill-has-mild-to-moderate-side-effects-in-early-trial 2024-09-11T01:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/f8ba38d73bbd45d0/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntington-s-disease-network-and-enroll-hd-2024 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce24f025164a4b3c/cellworks-biosimulation-platform-predicts-chemotherapy-benefit-in-nsclc-patients-beyond-pd-l1-status 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6d84e4d3fcae14cb/highly-accurate-telix-s-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the 2024-09-10T22:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/5dca3212c23ec31e/prophylactic-dexamethasone-regimen-reduces-infusion-related-globenewswire 2024-09-10T22:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/a22a718eb150a7b1/walgreens-boots-alliance-inc-wba-td-cowen-9th-annual-futurehealth-conference-transcript 2024-09-10T22:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/d15c245dc8674a02/dr-leighl-on-patient-satisfaction-and-resource-utilization-from-paloma-3-in-nsclc 2024-09-10T22:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/47d387ef7c4fcf40/avistone-announces-results-from-a-sponsored-clinical-research-program-studying-morningstar 2024-09-10T21:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/87f77999113b513b/easd-2024-cardiovascular-and-inflammatory-markers-reduce-after-orforglipron-treatment 2024-09-10T21:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/62b5df3de2097746/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-placera 2024-09-10T21:20:44+00:00 weekly 0.7 https://trial.medpath.com/news/c4e09c1d4f6de538/fda-action-update-august-2024-approvals-designations-and-clearances 2024-09-10T21:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/2a16e7d6a6b4590c/bridgebio-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation 2024-09-10T20:50:48+00:00 weekly 0.7 https://trial.medpath.com/news/2a908cfcc802d6f1/tofacitinib-effective-for-ankylosing-spondylitis-regardless-of-baseline-crp-level 2024-09-10T20:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/11fc6f53df90cdae/rate-of-cardiovascular-adverse-events-myocarditis-may-be-low-in-trials-assessing-icis 2024-09-10T20:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/7412b0af678a02a7/mirvetuximab-soravtansine-shows-efficacy-in-ovarian-cancer-despite-dose-adjustments 2024-09-10T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/0d584e3e46769300/fda-grants-510-k-clearance-to-sonic-incytes-velacur-r-determined-fat-fraction-vdff-a 2024-09-10T18:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/6d8b94de408b2853/pan-covid-new-drug-sns812-achieves-superiority-in-phase-2-study-biospace 2024-09-10T17:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/68e952f043129ec3/vasa-therapeutics-lead-drug-candidate-enters-clinical-trials-contract-pharma 2024-09-10T17:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/0b5654fef15b9684/overcoming-failures-lessons-from-ipf-clinical-trials-in-the-past-year 2024-09-10T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/d26a53de4268bb5e/dm-clinical-research-partners-with-brain-and-pain-care-and-sleep-care-clinic-for-new 2024-09-10T17:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/1826bda0d11f977e/phase-ii-study-of-taletrectinib-shows-clinically-meaningful-overall-response-and-prweb 2024-09-10T17:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/1ca56439c4d7604f/atamyo-dion-foundation-partner-to-expand-lgmd-study-into-us 2024-09-10T17:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/0533f89e089b2674/hope-vs-hype-seeking-truth-in-recent-prilenia-headlines-hdbuzz 2024-09-10T17:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/f89510365d8a3cc9/tackling-medchem-bias-one-functional-group-at-a-time 2024-09-10T17:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/f57bd524093bbe3b/pridopidine-now-under-review-in-europe-as-huntington-s-treatment 2024-09-10T16:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/dd9fa5805c0304e7/why-a-promising-breast-cancer-drug-doesn-t-work-and-how-to-improve-it 2024-09-10T16:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/a6f535f2b4d61448/patients-with-namd-successfully-switch-from-aflibercept-to-ranibizumab 2024-09-10T15:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/2ff9d77d0844fb6c/reflections-on-neonatal-erythropoietin-neuroprotection-studies-jama-network 2024-09-10T15:34:45+00:00 weekly 0.7 https://trial.medpath.com/news/2c41d0399ee217f2/fda-grants-clearance-for-immunis-phase-ii-sarcopenic-obesity-trial-yahoo-finance 2024-09-10T15:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/40b13ab616415bda/leapfrog-bio-screens-clinical-stage-drugs-to-jump-into-cancer-markets 2024-09-10T15:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/676d853f552344b4/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg 2024-09-10T15:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/dadd590b45da9ff7/gene-therapy-for-inherited-retinal-dystrophy-shows-promise-inside-precision-medicine 2024-09-10T14:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/d76e8381a22e619b/the-relationship-between-participant-diversity-and-dct-use-in-clinical-trials 2024-09-10T14:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/e0b8c6e3b34892a9/telo-genomics-assessing-mrd-status-in-telo-dmrd-study-biospace 2024-09-10T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/0d3b9e0e65ddf0cc/common-diabetes-drug-slows-growth-of-normal-cells-carrying-cancer-mutation-finds-study 2024-09-10T14:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/5b12a098b74917c2/incannex-healthcare-lands-60-million-financing-deal-green-market-report 2024-09-10T14:43:04+00:00 weekly 0.7 https://trial.medpath.com/news/376df94edbb2849c/uk-study-lifetime-statin-therapy-proves-cost-effective-for-seniors-regardless-of-cvd-history 2024-09-10T14:30:48+00:00 weekly 0.7 https://trial.medpath.com/news/df6a7ca7f9a90c37/roivant-creates-new-vant-to-license-bayer-s-pulmonary-hypertension-drug-biospace 2024-09-10T14:22:59+00:00 weekly 0.7 https://trial.medpath.com/news/2b000060244d7928/buy-rating-justified-for-iterum-therapeutics-amid-anticipated-fda-approval-of-sulopenem-for-uutis 2024-09-10T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/f5fc5a623bce2573/oncohost-accepted-to-present-poster-demonstrating-prophet-r-s-application-in-renal-cell 2024-09-10T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/7a04899e0fd0e3c1/verona-pharma-a-post-fda-approval-analysis-nasdaq-vrna-seeking-alpha 2024-09-10T14:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/17674db15a86f820/travere-therapeutics-stock-target-boosted-buy-rating-held-on-fda-approval-investing-com 2024-09-10T13:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/7392912edb643648/five-biotech-news-stories-you-need-to-read-today 2024-09-10T13:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/ac7294f2d6328357/zokinvy-lonafarnib-the-only-fda-approved-treatment-for-hutchinson-gilford-progeria 2024-09-10T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/ae96a91cc2e4826c/daewoong-pharmaceutical-secures-ind-approval-for-dissolvable-microneedle-growth-hormone-patch 2024-09-10T13:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/cea91af444dd2dd9/know-your-tumor-uncovers-rare-mutation-leads-to-effective-treatment-for-patient 2024-09-10T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/9b0755585c168023/hyperbaric-oxygen-therapy-for-ulcerative-colitis-inventum-university-of-miami 2024-09-10T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/a7fde5e1e192c0c4/robert-duggan-wins-again-as-summit-lung-cancer-treatment-beats-keytruda-stat-news 2024-09-10T12:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/6c229c9bb3558cf5/corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for 2024-09-10T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/08861c5f4fe81ef5/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in 2024-09-10T12:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/4c288dff770bfceb/boehringer-ingelheim-reports-positive-results-from-trial-of-her2-lung-cancer-drug 2024-09-10T12:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/34ba76de151071af/integrative-radiopathomics-model-for-predicting-progression-free-survival-in-patients-with 2024-09-10T12:25:00+00:00 weekly 0.7